

## REVIEW ARTICLE

# Perioperative Nociception and Pain in Dogs and Cats - Part I: An Illustrative Text on Pain Mechanisms, Models and Assessment

Ubedullah KAKA<sup>1(\*)</sup> , Muhammad Waseem ASLAM<sup>1,2</sup> , Ali SAJID<sup>1</sup> , Hui Cheng CHEN<sup>1</sup> ,  
Yong Meng GOH<sup>3</sup> , Kirk A. MUNOZ<sup>4</sup> 

<sup>1</sup> Universiti Putra Malaysia, Faculty of Veterinary Medicine, Department of Companion Animal Medicine & Surgery, 43400, Serdang, MALAYSIA

<sup>2</sup> The Veterinary Referral Centre, Al Murooj Complex, Trade-Centre 2, DIFC, Dubai, UNITED ARAB EMIRATES

<sup>3</sup> Universiti Putra Malaysia, Faculty of Veterinary Medicine, Department of Veterinary Preclinical Sciences, 43400, Serdang, MALAYSIA

<sup>4</sup> The Ohio State University, College of Veterinary Medicine, Department of Veterinary Clinical Sciences, 43210, Columbus, UNITED STATE OF AMERICA

**(\*) Corresponding author:**

Ubedullah Kaka

Phone: +60 3 9769 4284 Cellular phone:

+60172037281 Fax: +60 3 8947 1971/1972

E-mail: [dr\\_ubedkaka@upm.edu.my](mailto:dr_ubedkaka@upm.edu.my)

How to cite this article?

**Kaka U, Aslam MW, Sajid A, Chen HC, Goh YM, Munoz KA:** Perioperative Nociception and Pain in Dogs and Cats - Part I: An Illustrative Text on Pain Mechanisms, Models and Assessment. *Kafkas Univ Vet Fak Derg*, 2026 (Article in Press).

DOI: 10.9775/kvfd.2026.36363

Article ID: KVFD-2026-36363

Received: 06.02.2026

Accepted: 10.05.2026

Published Online: 02.06.2026

**Abstract**

Effective perioperative pain management depends on a thorough understanding of pain mechanisms and reliable assessment methods. Pain serves as a vital protective mechanism, acting as an alarm for underlying disease, trauma, or surgical injury. In disease, it prompts investigation of causative factors, while in trauma or surgery, it encourages protection of injured tissues. Inadequate management of acute pain can lead to significant physiological and behavioral consequences, including stress hormone release, increased heart rate and blood pressure, behavioral alterations, delayed wound healing, chronic pain development, and prolonged hospitalization. Keywords included pain pathways, nociception, pain models, analgesics, multimodal analgesia, electroencephalography, algometry, ketamine, and lidocaine. The purpose of this review is to enhance clinicians' and researchers' understanding of acute pain and nociception in dogs and cats, with particular emphasis on perioperative settings. The physiological processes involved in pain transmission, modulation, perception, as well as peripheral and central sensitization are discussed. Additionally, commonly used subjective and objective pain assessment techniques, including behavioral scoring systems and physiological indicators, are reviewed to support accurate pain recognition. This review is presented in two complementary parts. Part I focuses on pain pathophysiology and assessment, forming the foundation for Part II, which evaluates pharmacological and multimodal analgesic strategies for perioperative pain management.

**Keywords:** Cats, Dogs, Nociceptive pathways, Pain assessment, Perioperative pain, Sensitization

## INTRODUCTION

Pain functions as a natural alarm to an underlying disease, trauma or surgery. In disease, it prompts investigation of the cause(s), whereas in trauma or surgery, it acts as a protective warning to safeguard the injured site against further damage. Absence or inadequate perception of pain may result in undetected disease progression and insufficient protection of injured tissues, ultimately leading to adverse outcomes. Poorly managed acute pain

can trigger stress hormone release and is associated with reduced activity, increased heart rate and blood pressure, behavioral alterations, shivering, hypersensitivity, aggression, vocalization, anorexia, weight loss, delayed wound healing, depression, transition to chronic pain, and prolonged hospitalization. Therefore, this review aims to discuss the pathophysiology, recognition, assessment, and management of acute pain in veterinary patients, with emphasis on improving animal welfare and clinical outcomes.



## DEFINITION: PAIN AND NOCICEPTION

The official definition of pain by the International Association for the Study of Pain (IASP) is: "An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" [1,2].

Clinically, pain can be classified as either acute or chronic. Acute pain results from an injury and ends with wound healing. Chronic pain lasts beyond acute pain or wound healing.

Generally, pain that persists for more than three months is considered chronic pain. This suggests that there is an ongoing slow change over time in the mechanism leading to chronic pain; and that there is not anything that otherwise causes "chronic pain" after three months. Typical example of causes of pain is surgical pain, trauma, or onset of acute disease, such as pancreatitis, whereas osteoarthritis, cancer and periodontal disease are examples of conditions in which chronic pain is seen. Surgical pain that exists beyond the expected time frame of acute pain is called chronic pain [1,3,4]. In animals, verbal communication is not comprehensible across different species, hence, making the task of pain assessment more challenging for clinicians and researchers [5]. It is highly important for a clinician to have a good understanding of pain physiology, pathways, and assessment methodology in order to treat it effectively.

Let us briefly consider why animals do not consciously perceive pain under general anesthesia. If pain perception is absent, one may question why physiological parameters such as heart rate, blood pressure, and respiratory rate increase in response to surgical stimulation during anesthesia, while animals may vocalize due to pain immediately upon recovery.

This phenomenon is explained by the process of nociception, which refers to the neural encoding and processing of noxious stimuli [6,7]. Nociception is distinct from pain in that it does not involve a conscious emotional experience; rather, pain requires processing at the level of the conscious brain. Under general anesthesia, cortical function and the emotional component of pain perception are suppressed. However, nociceptive pathways at the peripheral and spinal level may remain active.

As a result, surgical stimuli can continue to generate nociceptive input, leading to autonomic responses such as increases in heart rate, blood pressure, and respiratory rate, despite the absence of conscious pain perception. Importantly, once the animal recovers from anesthesia and cortical function is restored, this nociceptive input can then be perceived as pain, resulting in behaviors such as vocalization.


Nociception begins at the site of tissue injury, where specialized receptors termed nociceptors transduce noxious stimuli into electrical signals. These signals are transmitted through the nervous system for further processing. Thus, while nociception can occur in the absence of conscious pain, the perception of pain requires intact central processing and does not occur without nociceptive signaling.

### Nociceptors

The receptors characterised by free, non-encapsulated nerve endings that detect nociceptive (noxious) stimuli are called nociceptors. These are widely distributed in the skin and deep tissue, with their cell bodies located in dorsal root and trigeminal ganglia [1]. These nociceptors are peripheral terminals of primary afferent neurons. Mechanical, chemical and thermal stimuli can stimulate these receptors. Some nociceptors respond to only one of these stimuli (unimodal), whereas others respond to a variety of stimuli (polymodal) [6,7].

**Sensory Nerve Fibers:** Three classes of sensory nerve fibers have been described based on anatomy (myelination), function and speed of conduction. Large, myelinated group A $\alpha$  and A $\beta$  nerve fibers - these are low-threshold fibers with a diameter of 10  $\mu$ m and detect low-intensity, innocuous (touch, vibration, pressure, and limb movement) stimuli with high velocities of 30 to 100 m/s. Smaller, lightly myelinated A $\delta$  fibers and nonmyelinated and nonmyelinated C fibers - A $\delta$  and C fibers are high threshold fibers and are more predominant (>90%) than low threshold fibers [8]. A $\delta$  fibers conduct at a speed of 5 to 30 m/s and detect sharp pricking pain and result in rapid withdrawal from the stimulus as a primary warning (fast pain). C fibers conduct at speeds of 0.5 to 2.0 m/s and detect slow burning pain (slow pain) and are primarily involved in nociceptive signalling. Both A $\delta$  and C fibers supply to the skin and deep somatic or visceral structures [1]. Silent nociceptors represent a subset of C-fiber afferents characterized by a high activation threshold and minimal or absent responsiveness to mechanical or thermal stimuli under normal physiological conditions. Exposure to inflammatory mediators significantly decreases their threshold, and these previously silent nociceptors become stimulated and sensitive to a variety of stimuli [1,9].

Activation of pain receptors in the peripheral tissue (skin) generates action potentials that are conveyed to the central nervous system (CNS) through A $\delta$  and C nerve fibers. Sharp, pin prick and injurious pain (first pain) are transmitted by fast A $\delta$  fibers. However, dull aching pain (second pain) is transmitted by slow C fibers. The primary sensory neurons enter the spinal cord and synapse with neurons in the dorsal horn. From the dorsal horn, second-order neurons having long axons cross in the



**Fig 1.** Anatomy of the spinal cord. Classified into gray and white matter. The gray matter is divided into three distinct regions: dorsal horn, intermediate zone, and ventral horn, which are further subdivided into ten undemarcated laminae

anterior commissure and pass through the spinothalamic tract towards the brain. Some long axons that synapse with C neurons do not cross but pass cranially in the ipsilateral anterolateral spinal pathway. Fibers from the anterolateral spinal pathway terminate in the thalamus from where signals are passed to the sensory cortex and other centers in the CNS, where pain perception takes place. Pain consists of three main components: a sensory-discriminatory component (temporal, spatial, thermal/mechanical), an affective component (subjective and emotional, describing associated fear, tension, and autonomic responses) and an evaluative component, describing the magnitude of the quality (e.g. stabbing/pounding; mild/severe) [1,10-12].

## ANATOMY OF THE SPINAL CORD

*Fig. 1* illustrates the anatomy of the spinal cord which is classified into gray and white matter. In a broader overview, the gray matter is divided into three distinct regions: dorsal horn, intermediate zone, and ventral horn, which are further subdivided into ten undemarcated laminae (*Fig. 1*). The dorsal horn comprises laminae I to VI, the intermediate zone comprises lamina VII, the ventral horn comprises laminae VIII to IX, and lamina X surrounds the central canal of the spinal cord [13]. In primary afferent fibers, the thinly myelinated A $\delta$  fibers project to lamina I and V, thick myelinated A $\beta$  fibers project to lamina III, VI and V, while, non-myelinated C fibers project to lamina I and II in the dorsal horn of the spinal cord.

Electrophysiological studies have revealed that spinal cord neurons within lamina I generally respond to noxious stimuli, neurons in laminae III and VI respond to non-noxious stimuli, and neurons in lamina V receive both noxious and non-noxious information. Neurons in lamina V are called wide dynamic range neurons (WDR) given their response to a range of intensities from non-

noxious to noxious stimuli [14]. Neurons in lamina I and V carry nociceptive information to the thalamus and brainstem via spinothalamic and spinoreticulothalamic tracts. The spinothalamic tract is relevant to the sensory-discriminative aspect of the pain experience, whereas the spinoreticulothalamic tract is more relevant to poorly localized pain. From the brain stem and thalamus, the information reaches the cortical structures [14].


## NOCICEPTIVE PATHWAY

Nociceptive pathways comprise of ascending and descending pathways. Propagation of noxious information from the site of injury towards the brain occurs through the ascending pathway, whereas movement of information from the brain to the periphery occurs through the descending pathway. This processing of information occurs through the phenomenon of nociception.


### Nociception

Nociception is a phenomenon by which intense mechanical, thermal or chemical noxious stimuli are detected by nociceptors, a subpopulation of peripheral nerve fibers [14]. The process of nociception takes place in a few steps: transduction, transmission, modulation projection and perception (*Fig. 2, Fig. 3*).

When tissue is damaged, noxious stimuli are translated into nociceptive signals through a process called transduction. Transmission is the process by which these signals from the periphery reach the spinal cord. Along the nociceptive



**Fig 2.** Illustrative summary of the ascending pathway of nociception. When tissue is damaged, noxious stimuli are translated into nociceptive signals through a process called transduction followed by transmission, modulation, projection and perception. Phases of the pain pathway, types of nerves involved, and anatomical regions have been labelled



**Fig 3.** The descending inhibitory pathway. Periaqueductal gray matter (PAG) and rostroventral medulla (RVM) are the main regions involved in the descending inhibitory pathway. Both centers have high concentrations of opioid receptors and endogenous opioids. The PAG receives inputs from brain regions of interest, such as the thalamus, hypothalamus and reticular formation, and sends to the nucleus raphe magnus and locus coeruleus. These centers project to the dorsal horn to inhibit pain transmission

pathway, signals undergo both inhibitory and excitatory processes, collectively termed modulation. This process regulates the intensity and transmission of nociceptive input through mechanisms within the peripheral nervous system, spinal cord, and brain.

Projection refers to the ascending transmission of nociceptive signals from the spinal cord to higher brain centers. This process ultimately leads to perception, the final stage of nociception, in which these signals are consciously interpreted as pain [15].

**Transduction:** When nociceptors are stimulated by noxious stimuli (heat, cold, chemical or mechanical), this results in a conformational change in the receptor. With this change in the receptor the noxious signals are converted into electric current by activating the opening of depolarizing cationic ion channels or the closing of

outward potassium channels [16]. Various molecules, such as members of the transient receptor potential (TRP) cation channel family, acid-sensitive ion channels (ASIC) and purine-activated ligand-operated ion channels, have been identified in the process of transduction. The TRP family members include, transient receptor potential subfamily ankyrin (TRPA), transient receptor potential subfamily canonical (TRPC), transient receptor potential subfamily melastatin (TRPM), and transient receptor potential subfamily vanilloid (TRPV) [17,18] transduce thermal and chemical signals. Certain receptors of the TRP family are activated by a decrease in local pH, or chemical ligand, i.e., capsaicin (the vanilloid constituent that provides the “hot” in hot peppers). The TRPA and TRPM share the role of transducing thermal signals with many two-pore potassium channels (K2P) and Na<sub>v</sub>1.8 channel [19]. Ischemia and inflammation result in an increase in hydrogen ion concentration, which activates ASIC. Damage to cells leads to excesses of adenosine triphosphate (ATP) that signal to purinergic receptors; P2X is a purine-activated ligand-operated ion channel, and P2Y is a G-protein-coupled receptor. Bacterial lipopolysaccharides and inflammatory cytokines result in expression of the bradykinin-1 (B1) receptor, while the bradykinin-2 (B2) receptor is constitutively expressed. Activation of B1 and B2 forms inositol 1,4,5-triphosphate and diacylglycerol with subsequent increases in intracellular calcium concentration. Activation of bradykinin B<sub>2</sub> receptors leads to the production of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and prostacyclin (PGI<sub>2</sub>), which act to sensitize nociceptors and amplify the nociceptive signal [20]. Piezo channels, TRPA1 and TRPV4, transient Ca<sup>2+</sup> channels, and at least three K2P channels are among the transducers known to be involved in mammalian mechanotransduction [21-26]. Clinically, activation of these receptors leads to heat hypersensitivity as a result of tissue injury and inflammation, contributing significantly to the development of painful condition.

Recent research has revealed that TRPV1-4 channels play a role in transduction of chemical and thermal stimuli and are expressed in afferent nociceptors, and pain-sensing neurons [27]. Two of the channels, TRPA1 and TRPM8, are activated by cold temperature [28]. These channels have been proposed as a therapeutic target due to their association with heat and cold thermal stimuli. Further research into nociception will facilitate the development of more effective and targeted therapeutic strategies for the management of pain and its associated pathologies.

**Transmission:** Once the successful transduction of nociceptive stimuli by primary afferent neurons takes place, different voltage-gated ion channels are activated by receptor potentials. Voltage-gated sodium and potassium channels play significant roles in the generation of action

potentials, which transmit nociceptive signals to the dorsal horn [14]. Tetrodotoxin (TTX)-resistant channels, TTX-sensitive channels and voltage-gated sodium channels ( $\text{Na}_v$ ) 1.1, 1.6, 1.7, 1.8 and 1.9 are different types of voltage-gated sodium channels [29]. Tetrodotoxin (TTX)-sensitive channels cause rapid depolarisation and are responsible for acute pain signal transmission. Tetrodotoxin (TTX)-resistant channels are responsible for transmitting slow, burning, or inflammatory pain signals (neuropathic pain). Clinically these receptors are related to several chronic pain conditions, manifested as hyperalgesia and allodynia. When the threshold potential is reached, an action potential is generated, allowing propagation of the nociceptive signal along the neuron. This action potential arises through the coordinated opening of voltage-gated sodium ( $\text{Na}^+$ ) and calcium ( $\text{Ca}^{2+}$ ) channels, which mediate membrane depolarization, along with the relative reduction in potassium ( $\text{K}^+$ ) efflux that otherwise contributes to membrane hyperpolarization [20]. Nociceptive signals are transmitted to the CNS via the dorsal horn of the spinal cord. The cell bodies of primary afferent nociceptors are located in the dorsal root ganglia. Within the dorsal horn, primary afferent neurons synapse with secondary neurons and interneurons across different laminae. These connections play a critical role in the integration, modulation, and further transmission of nociceptive information to higher centers of the brain.

**Modulation or Descending Inhibitory Pathway:** The pain signals in the dorsal horn are modulated by efferent neurons that descend from the CNS. In addition to antinociceptive pathways, descending pathways exist with the ability to modify the pain reaction. The descending pathways include thalamocortical structures, pons of the brain stem, the PAG of the midbrain, the rostroventral medulla (RVM), and the dorsal horn; PAG and RVM are generally considered core regions of this important system (Fig. 3) [30,31].

Modulation of plasticity augments sensitivity (excitatory) to incoming nociceptive signals; this modulation takes place after release of excitatory neurotransmitters such as substance P, glutamate, and calcitonin gene-related peptide (CGRP). Augmented sensitivity is facilitated by upregulation of excitatory neurotransmitter receptors (Structural Plasticity) and decreased signal intensity required to induce conformational changes in receptor proteins (functional plasticity). On the other hand, sensitivity of secondary neurons to incoming information is decreased due to hyperpolarization in the postsynaptic nerve terminals or decreased influx of calcium into presynaptic terminals. This decrease in sensitivity (inhibitory) occurs after the release of GABA, endorphins and enkephalins, norepinephrine, and serotonin acting at some serotonin receptors [30,31].

“On” and “Off” cells are the unique populations within the RVM. Off-cells hyperpolarize in response to activation of the spinothalamic tract and decrease the transmission of the streams of nociceptive action potentials in the brain stem [32]. On the other hand, nociceptive information from the spinothalamic tract causes excitation of on-cells and engages parabrachial, hypothalamic, cingulate, insular, and septohippocampal pathways subserving arousal and aversive reactions to pain [33]. These on-cells appear to be important in producing hyperalgesia by maintaining central sensitization after peripheral tissue injury [32,34]. This understanding of on-cells and central sensitization is crucial for managing chronic pain conditions, where hyperalgesia can significantly impact a patient’s quality of life.

**Projection and Perception:** The dorsal horn of the spinal cord possesses bodies of second-order nociceptive neurons. From the dorsal horn, these second-order neurons carry nociceptive impulses through their axons projecting to higher CNS centers, which are responsible for the processing of nociceptive information. The cortical regions involved in the pain processing are the primary and secondary somatosensory cortex and its vicinity in the parietal operculum, insula, anterior cingulate cortex and prefrontal cortex. These are collectively called pain matrices [35]. Imaging studies have revealed that the thalamus, insula, hypothalamus and ventral tegmental area (VTA) are associated with the stimulation of C fibers in response to noxious stimulation in rats [36].

The wide dynamic range and high threshold neurons (spinothalamic tract) pass through the pons, medulla and mid-brain to terminate in specific portions of the thalamus. The somatosensory cortex receives nociceptive signals from the thalamus. The reticular formation also receives collateral branches from the spinothalamic tract. Emotional exhibition of pain and sensory discrimination takes place when the signals pass through these tracts. Emotional components of pain, including somatic and autonomic motor reflexes as well as increased arousal is probably the function of the reticular formation [37,38].

Peripheral nociceptors ( $\text{A}\delta$  and C fibers), responsible for transduction and transmission are slowed down or blocked by anaesthetics at the periphery. Dorsal root ganglia serve a role of relay station for nociceptive information to the CNS, which is the area of modulation of the nociceptive information. General anaesthetics suppress transmission of nociceptive signals within ascending pathways, including the spinothalamic tract, thereby preventing conscious perception of pain. The brain stem regulates respiration and CVS; anaesthetics have minimal depression effects on these centers compared to the thalamus and cortex, responsible for nociception and pain [39-42].

## MECHANISMS OF SENSITIZATION

Sensitization is defined by the International Association for the Study of Pain (IASP) as the 'Increased responsiveness of nociceptive neurons to their normal input, and/or recruitment of a response to normally subthreshold inputs. Peripheral sensitization refers to an increased responsiveness in the nociceptive neurons in the periphery, whereas central sensitization refers to an increased responsiveness of nociceptive neurons in the central nervous system (CNS) to their normal or subthreshold afferent input' [43,44].

Hyperalgesia and allodynia are typical clinical characteristics of sensitization. Hyperalgesia is an exaggerated and prolonged response to a noxious stimulus, while allodynia is a pain response to a low-intensity, normally innocuous stimulus such as light touch to the skin or gentle pressure. Hyperalgesia and allodynia are consequences of peripheral and central sensitization [1].

### Mechanism of Peripheral Sensitization

Tissue damage during surgery results in the accumulation of endogenous factors produced from stimulated nociceptors and non-neural cells that reside within or

infiltrate the injured area. These non-neural cells include mast cells, basophils, platelets, macrophages, neutrophils, endothelial cells, keratinocytes, and fibroblasts. Neuropeptide substances such as substance P, nerve growth factor (NGF) and calcitonin gene-related peptide (CGRP) are produced after the noxious stimulus has been recognized by the sensory nerve endings of peptidergic nociceptors. The release of substance P and CGRP induces vasodilatation, plasma extravasation, and other effects, thus producing 'neurogenic inflammation' [45]. Discharge of vasoactive substances from mast cells and increased vascular permeability leads to neurogenic edema [46].

Histamine and serotonin are also released as a result of increased permeability and act as algogenic substances. Substance P, NGF, kinin and interleukin-I cause degranulation of mast cells, releasing histamine, which acts on sensory neurons to produce pain and itching [47]. This activation of sensory neurons by histamine induces the discharge of neuropeptides and prostaglandins (PGs), resulting in aggravation of inflammation and hyperalgesia. Serotonin released from platelets and mast cells during injury is a major inflammatory mediator during the initial phase of inflammation. Serotonin directly stimulates sensory neurons via activation of the 5HT type-3 (5HT<sub>3</sub>) receptor. Norepinephrine is released as a result of stimulation of the sympathetic nervous system in response to nociceptive impulses. Norepinephrine accelerates sensitization of the nociceptors, creating another vicious cycle [48]. Fig. 4 illustrates the vicious and complex mechanism of peripheral sensitization.

In summary, these mediators augment the excitability of nerve fibers, resulting in a decreased activation threshold of nociceptors and, consequently, amplifying the sensitivity to thermal and mechanical stimuli in the surrounding injured tissue. Subsequently, silent nociceptors are also recruited and activated [16]. In addition to neurotrophin injury, these mediators also cause the release of cytokines; among them, interleukin- $\beta$  (IL- $\beta$ ), IL-6 and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) are the key players in nociception. These cytokines act on nociceptors and contribute to pain hypersensitivity by increasing the production of PGs, bradykinin and extracellular protons [14]. This cascade of events produces an "inflammatory soup" [49]. This inflammatory soup bathes peripheral nociceptors, consequently decreasing their activation threshold or augmenting their sensitivity to pain, resulting in peripheral sensitization [50].

Peripheral sensitization is characterized by allodynia and hyperalgesia. In allodynia, activation thresholds are decreased, resulting in pain from the stimulus that does not normally provoke pain. In hyperalgesia, there is increased pain from the stimulus that normally provokes pain [2]. This hyperalgesia at the site of injury is called




Fig 4. Illustrative summary of peripheral sensitization, where a vicious cycle of neural and non-neural mediators created an inflammatory soup to develop peripheral sensitization. This cascade of events produces an "inflammatory soup", which bathes peripheral nociceptors, consequently decreasing their activation threshold or augmenting their sensitivity to pain, resulting in peripheral sensitization

primary hyperalgesia, which is commonly observed following surgery and other types of trauma. However, hypersensitivity at the site of uninjured skin around the wound is called secondary hyperalgesia, which is the function of central sensitization<sup>[51]</sup>. Activation of silent nociceptors results in mechanical hypersensitivity<sup>[10]</sup>, which is an important feature of inflammatory pain and a result of central sensitization<sup>[49]</sup>.

### Mechanism of Central Sensitization


Central sensitization takes place at the level of the dorsal horn. When the noxious stimulus is encoded into an electrical signal, these signals are then transmitted to secondary neurons in the dorsal horn of the spinal cord from the site of injury by primary afferent nerve fibers. The secondary neurons are divided into two classes, "nociceptive specific" or "high threshold" and "wide dynamic range" or "convergent". Nociceptive-specific neurons respond exclusively to noxious stimuli from C and A $\delta$  fibers. Wide dynamic range neurons respond to both noxious and non-noxious stimuli. Bombardment of WDR and nociceptive-specific neurons by afferent C fibers in the dorsal horn of the spinal cord results in a progressive increase in the frequency of firing of second-order spinal neurons at a frequency above 0.5 Hz. This is also known as windup, in which magnesium blocking of the N-methyl-D-aspartate (NMDA) receptors is removed,

rendering them for glutamate activation<sup>[20]</sup>.

Glutamate is the main and fast neurotransmitter in the CNS and plays a major role in nociceptive transmission. Glutamate acts at  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, NMDA receptors, kainate (KA) receptors, and metabotropic glutamate receptors. Glutamate-activated NMDA receptors are involved in the mechanisms that result in increased synaptic efficiency. Phosphorylation of NMDA receptor activates its mobility from intracellular store to synaptic membrane, enhancing its responsiveness to glutamate by removal of the voltage-dependent magnesium ( $Mg^{++}$ ) ion block, thereby favoring the open-state configuration (Fig. 5)<sup>[52]</sup>. Glutamate brain-derived neurotrophic factor (BDNF) and substance-P activate membrane-bound receptors (NMDA, metabotropic glutamate receptor, neurokinin receptor and tropomyosin receptor kinase B), resulting in increased intracellular calcium and activation of intracellular molecular signaling cascades, including calcium-calmodulin-dependent kinase [CaMK], protein kinase C, protein kinase A, neuronal cyclooxygenase (COX), nitrous oxide synthase and activation of other calcium-sensitive transcription factors. Consequently, this cascade assists in further receptor function and expression of cell surface receptors<sup>[20]</sup>.

Phosphorylation of ion channels and membrane receptors are the post-translational changes caused by activation of the gamma isoform of protein kinase-C. This causes an increase in neuronal excitability for tens of minutes even after the initial stimulus has stopped. This recruits responses to subthreshold stimuli and mediates the change from short-term to long term hyperexcitability of nociceptive spinal cord neurons. The increase in excitation along with a reduction in the inhibition of spinal cord neurons results in central sensitization<sup>[10]</sup>. However, the neurons in the dorsal horn of the spinal cord are also excited by other second messenger pathways that are activated by brief and intense C-fiber signals<sup>[53]</sup>. Within seconds of exposure to strong nociceptive stimuli, central sensitization develops, resulting in enhanced nociceptive facilitation that can persist for hours beyond the initial stimulus<sup>[54]</sup>.

There is evidence that stimulation of glial cells within the dorsal horn of the spinal cord also plays a crucial role in the creation and maintenance of pathological pain<sup>[55]</sup>. When nerve trauma or inflammation occurs, glial cells become activated, which leads to the production of several proinflammatory mediators<sup>[56,57]</sup>. Crucial proinflammatory cytokines include IL-6, IL-1b and TNF- $\alpha$ <sup>[56]</sup>. Chemokines such as monocyte chemoattractant protein and macrophage inflammatory protein-2 recruit neutrophils and macrophages from the bloodstream into the neurons<sup>[57]</sup>.



**Fig 5.** Illustrative summary of central sensitization compared with acute pain or normal nerve stimulus (Bombardment of WDR and nociceptive-specific neurons by afferent C fibers results in a progressive increase in the frequency of firing of second-order spinal neurons at a frequency above 0.5 Hz. This is also known as windup, in which magnesium blocking of the N-methyl-D-aspartate (NMDA) receptors is removed, rendering them for glutamate activation. Glutamate is the main and fast neurotransmitter in the CNS and plays a major role in nociceptive transmission. Glutamate acts at  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, NMDA receptors, kainate (KA) receptors, and metabotropic glutamate receptors. Glutamate-activated NMDA receptors are involved in the increased synaptic efficiency. Phosphorylation of NMDA receptor activates its mobility from intracellular store to synaptic membrane, enhancing its responsiveness to glutamate by removal of the voltage-dependent magnesium ( $Mg^{++}$ ) ion block, thereby favoring the open-state configuration)

Thus, an increased pain state, central sensitization, can be established and sustained by these neuroexcitatory chemicals released after glial cell activation. Central sensitization results in allodynia and hyperalgesia by increasing the receptive field (response area) and tissue sensitivity to thermal, mechanical, and chemical stimuli [58]. The difference between central and peripheral sensitization is that central sensitization allows low threshold sensory fibers ( $A\beta$ ) to cause pain by increasing the excitability of spinal neurons and produces changes in spinal cord sensory processing. In contrast, peripheral sensitization enables low-intensity stimuli to induce pain by stimulating sensitized  $A\delta$  and C fibers. In central sensitization pain signals are produced by low-threshold  $A\beta$  mechanoreceptors, which normally produce touch, vibration, and movement pressure (nonpainful) signals. Central sensitization has a crucial contribution to postsurgical hypersensitivity [10].

Thus, surgical trauma contributes to postoperative pain hypersensitivity via peripheral and central sensitization: two different but collaborative mechanisms [59]. In patients undergoing ovariohysterectomy, this phenomenon of peripheral and central sensitization has been demonstrated clinically by an increase in pain score in response to palpation at surgical and distant sites [60-62].

## LONG-TERM POTENTIATION

Long-term potentiation (LTP) has been reported as an important form of synaptic plasticity in nociceptive spinal pathways, and its mechanism resembles central sensitization. In acute and chronic pain states, it has been suggested as one of the cellular mechanisms contributing to pain amplification. A noxious stimulus is mandatory to develop a typical spinal LTP and therefore speculated to contribute to acute and chronic forms of pain that develop post-operatively or from an initial painful event, neuropathy or peripheral inflammation [63,64].

LTP induction at spinal C-fibre synapses requires a rise in post-synaptic  $Ca^{2+}$  concentration. Post-synaptic  $Ca^{2+}$  rises by opening of the post-synaptic NMDA and  $Ca^{2+}$ -permeable AMPA receptors, T-type voltage-gated calcium channels and release of  $Ca^{2+}$  from intracellular calcium stores. All these calcium sources trigger the activation of metabotropic glutamate or neurokinin-1 receptors. Finally, this rise in post-synaptic  $Ca^{2+}$  activates  $Ca^{2+}$ -dependent signaling pathways involving calcium calmodulin-dependent protein kinase II (CaMKII), protein kinase C, and nitric oxide synthase (NOS) [65-67].

Currently, the evidence is clear for the post-synaptic  $Ca^{2+}$ -dependent form of LTP induction in spinal cord lamina I neurons. Induction of LTP at C-fibre synapses requires activation of group I metabotropic glutamate receptors [68]

and co-activation of the NK1 and NK2 receptors. It also requires the opening of ionotropic glutamate receptors of the NMDA type [69-71] and T-type voltage-gated calcium channels [70,71]. Substance P-mediated stimulation of NK1 receptors may directly augment single NMDA channel opening [72] and NMDA receptor-mediated electric signals in lamina I neurons. All this may result into a significant increase in post-synaptic intracellular calcium [70].

In an *in vitro* setting, it has been shown that an increase in post-synaptic intracellular  $Ca^{2+}$  is crucial for LTP induction, and there is a linear correlation between the amount of Intracellular  $Ca^{2+}$  increase and the amount of LTP [61]. In a previous study, the data demonstrated that LTP-induced stimuli caused a significant rise in intracellular  $Ca^{2+}$  in lamina I neurons, and this rise was not only observed during slice preparations but also in intact animals [71]. Therefore, it was not surprising that signal transduction involves  $Ca^{2+}$ -dependent pathways, including activation of CaMKII, NOS, protein kinase A and C, phospholipase C, inositol triphosphate-3 (IP3) receptors and extracellular signal regulated kinase (ERK), including members of the mitogen-activated protein kinase family (MAPK) [22,70,73-76].

In summary, significant similarities exist between central sensitization and spinal cord long-term potentiation, and both require NMDA receptors and involve key signaling transduction pathways, including extracellular signal-regulated kinase, protein kinase C, Src, and dependence of protein synthesis and gene transcription [64]. The salient features of acute central sensitization are short latency (seconds) by intense, repeated, or sustained nociceptive stimuli, which typically can persist for several hours in the absence of further nociceptive stimulus [77]. However, an additional mechanism may be needed for maintenance of late-phase long-term potentiation (greater than 4 h). Because it is technically challenging to follow long-term potentiation over time, it is unknown if there is ongoing spinal long-term potentiation, months after painful insults [64].

NMDA receptors play a crucial role in the spinal pain process. Noxious and non-noxious stimuli stimulate the sensory dorsal horn neurons through NMDA. This suggests a role for NMDA receptors in nociception, as well as in the development of behavioral hyperalgesia and allodynia. Various NMDA antagonists reduced thermal hyperalgesia, mechanical hyperalgesia/allodynia, and spontaneous nociceptive behavior. Thus, surgical stimuli can trigger LTP in nociceptive pathways resulting in chronic post-surgical pain (neuropathic pain); clinically, manifested as hyperalgesia and allodynia [78]. Understanding the NMDA, AMPA receptors, calcium dependent pathways, and other molecules involved in LTP, and drugs to antagonize these pathways could be a way forward to manage or prevent chronic pain.

Mechanism of LTP has been reported to be associated with crucial physiological functions such as learning, memory, cue reward-learning and fear in various regions in the brain, for example, in hippocampus, neocortex, thalamo-amygdala and lateral amygdala. Whereas, in the dorsal horn of the spinal cord LTP is associated with pathological pain or chronic pain<sup>[79]</sup>. Lack of understanding of this association of LTP across various brain regions makes it challenging to design region-specific therapeutic interventions without affecting unrelated areas. Many molecular pathways involved in LTP might have a negative effect on other physiological processes, such as addiction potential, normal sensory processing, memory and learning. These could be possible challenges in translating LTP research into effective clinical therapies.

## ASSESSMENT OF PAIN

Relieving the pain and suffering of the animals is the prime obligation of the veterinary clinician and researcher. It has been demonstrated that painful stimuli in humans cause comparable behavioral and physiological changes to those in other nonhuman species<sup>[5]</sup>. Human verbal and physical communication help clinicians and researchers evaluate pain. The lack of this communication ability makes it difficult and challenging to assess pain. Dogs and cats likely perceive pain in a manner similar to humans due to the presence of comparable, if not highly conserved, neurotransmitters and neural pathways involved in nociceptive processing<sup>[5]</sup>. Assessment and recognition of pain is an essential part of animal care and veterinary clinical practice. Quantitative assessment of pain in animals is a challenge to both researchers and clinicians and hinders objective measurement of the efficacy of analgesics. The ability to objectively measure pain is a pre-requisite to compare the efficacy of analgesics, which is difficult in animals because they cannot communicate directly<sup>[80]</sup>. Various models/methods of pain assessment, including behavioural<sup>[81]</sup>, neurohumoral<sup>[82]</sup> and neurophysiological<sup>[83]</sup> have been used in veterinary research.

### Basic Animal Pain Model

Research studies in humans and animals exploring the mechanism underlying acute pain as well as evaluating the analgesic effects of the drugs require appropriate use of stimulus to instigate the sensation. This stimulus must be non-invasive, repeatable and quantifiable<sup>[80,84]</sup> to obtain an appropriate response. Electrical, mechanical, thermal and chemical stimuli are four basic types of nociceptive models used to study the analgesic effects of the drugs in question. The end point of these stimuli is the various withdrawal reflexes or behavioral responses<sup>[80,84]</sup>.

**Electric Stimulation:** A painful electrical stimulus can be helpful to assess the effectiveness of centrally acting

agents. Electrical stimuli are non-invasive, quantifiable and reproducible and produce synchronized afferent signals. However, there are some disadvantages of the electrical stimulus, such as it is not a natural stimulus felt by animals in a normal environment. Furthermore, it bypasses the transduction mechanism (circumventing the transduction process at sensory receptors) and directly stimulates all peripheral afferent fibers ( $A\beta \rightarrow A\delta \rightarrow C$  fibers)<sup>[85]</sup>. Electric stimulation has advantages in studies where effects of the drugs are assessed on the CNS, when administered systematically. Any effect will be of central origin because of the bypassing mechanism of the transduction process, provided that the drug has no effect on peripheral fibers. Variation in the impedance of the tissue being stimulated is another disadvantage; nevertheless, this can be minimized by using a constant current stimulator and monitoring the voltage and current of the stimulus applied. When the electrical stimulus is applied, it initially activates  $A\beta$ , followed by  $A\delta$  and then C fibers<sup>[80]</sup>. A double pain phenomenon has been reported in humans, the first or "fast", a well localized, stinging type of pain as a result of activation of  $A\beta$  fibers and second or "slow", burning type of pain, more intense and difficult to localize, as a result of activation of C fibers<sup>[86]</sup>.

Various studies have reported the use of electric stimulation to evaluate a particular model and to evaluate the analgesic effects of test drugs. The electric current was used to stimulate the radial and tibial nerves, limbs, oral mucosa and periosteum to evaluate the microstrain gauge algometer for quantitative measurement of nociception<sup>[87]</sup> and validate the noxious stimuli techniques for determining the minimum alveolar concentration (MAC) in dogs<sup>[88]</sup>. Somatosympathetic reflexes of midazolam<sup>[89]</sup> and clonidine<sup>[90]</sup> were observed by electric stimulation of radial and tibial nerves in dogs. Electric stimulus was used on the dental pulp of the anaesthetized dogs to evaluate the analgesic effects of IV and intrathecal morphine compared to saline<sup>[91]</sup>. To evaluate the analgesic efficacy of low-dose ketamine in conscious dogs, Bergadano et al.<sup>[92]</sup> used a constant current device with a maximum voltage of 100 V and a maximal current of 40 mA to test a repetitive nociceptive stimulus. To evaluate the effects of tramadol, morphine and parecoxib on electroencephalography (EEG), Kongara et al.<sup>[93]</sup> used an electric current of 50 V at 50 Hz for 2 seconds on the right hind limb of dogs. A similar stimulus has been reported by Kaka et al.<sup>[94]</sup> in dogs.

In summary, various models have been developed for the quantitative evaluation of the antinociceptive effects of drugs in dogs. None of the models are ideal for use in dogs, with each having advantages and disadvantages. Nevertheless, these studies have demonstrated the use of electric stimuli in various models to assess the analgesic effects of drugs.

**Mechanical Stimulation:** In mechanical stimuli, pressure is applied against the surface of an organ to be tested. Application of the pressure initiates a nociceptive response; application of pressure can be progressive or coarse. The animal produces a behavioral response when the stimulus activates the nociceptors. These behavioral responses are the active withdrawal of the limb, guarding the test site or vocalization. The stimulus is withdrawn immediately at the time of an active response<sup>[81]</sup>.

Various models of mechanical nociception have been developed to evaluate the analgesic effects of drugs. Colorectal distension with a balloon was used in rats, a mechanical model of visceral nociception. Avoidance behavior along with reflex activities was recorded by electromyogram from the abdominal muscles; this model also developed tachycardia and increased arterial blood pressure. These parallel parameters were attenuated or even reversed using certain anaesthetic agents<sup>[95]</sup>. Other similar models were distension of the stomach<sup>[96]</sup> or duodenum<sup>[97,98]</sup>. The model of colonic distension has also been reported in rabbits<sup>[99,100]</sup> and dogs<sup>[101]</sup>.

Other different designs of mechanical devices have been used in dogs while working to quantify pressure applied to toes using a pair of Doyen intestinal forceps<sup>[102]</sup>; pneumatic device<sup>[103,104]</sup> and aluminum pliers with concave working ends<sup>[105]</sup>. The disadvantage of these techniques is that the rate of stimulus application cannot be controlled, and they can only be applied to the toes. In previous studies, an electronic method to measure joint tenderness in rheumatoid arthritis and tenderness of myofascial tissues was described by Atkins et al.<sup>[106]</sup> and Bendtsen et al.<sup>[107]</sup> respectively. Barnhart et al.<sup>[108]</sup> used a pressure device for mechanical pressure in dogs. The device consisted of a pneumatic cylinder powered by compressed nitrogen. When pressurized a bolt (2.54 cm in length) protruded out of cylinder pressing the skin overlying the periosteum of the medial aspect of the proximal tibia with enough pressure to cause transient discomfort to the dog. This method could not demonstrate the antinociceptive effects of morphine.

### Advanced Mechanical Models

In electronic measurement devices, the force applied via a rigid probe tip is quantified using an integrated load cell, which converts mechanical force into an electrical signal for precise measurement. A von Frey device works on the same principle and contains a tip that applies a gradually increasing force to the skin surface to create noxious stimuli. In some von Frey devices, fine hairs can also be used instead of a rigid tip that bent at a maximum force, and larger hairs can be used to retest until the subject reacts prior to hair bending. While working on the quantification of pain with a von Frey device on

humans<sup>[80]</sup> scientists have diverted their attention towards developing devices that can be used at the site of pain. Recently, a von Frey device has been used successfully to measure mechanical nociceptive threshold testing for analgesic trials of morphine in dogs<sup>[109]</sup>. For algometers refer to section- "Objective tools of pain assessment".

**Thermal Stimulation:** Heat causes selective stimulation of cutaneous receptors, resulting in specific activation of thermal and nociceptive fibers. This type of stimulation (with radiant lamps or contact thermodes and immersion of an animal's limb or tail in a thermostatic bath) results in the asynchronous stimulation of peripheral and central neurons because of the slow speed of cutaneous heating (<10°C/s). Thus, this model is not suitable for the study of a neural phenomenon seen in other sensory systems, where synchronous excitation of fibers is mandatory. However, thermal stimulation using a CO<sub>2</sub> laser thermal stimulator, results in the stimulation of nociceptive receptors only, as it does not actually contact the skin and provides controllable, safe, reproducible and specific noxious stimuli<sup>[80]</sup>.

Various models of heat sources have been developed and are being used in studies evaluating the analgesic efficacy of drugs. Barnhart et al.<sup>[108]</sup> used the thermal model to assess the antinociceptive action of morphine. There was no significant difference in thresholds between the control and morphine groups. The device was comprised of a linear, ramped-intensity, incandescent bulb housed in a metal cylinder. The device had a slow rate of heating and was dependent on skin contact. These factors may have influenced the consistency and accuracy of the measured responses and should be considered when interpreting the study results. Recently, Hoffmann et al.<sup>[110]</sup> used a thermal device containing a "thermal probe" as a temperature sensor and "heater element" in a thermally conductive epoxy that can be attached to the clipped thoracic wall of a dog or cat by an elasticated band in the center of an inflatable bladder that provides constant contact between the probe and the skin<sup>[111]</sup>. The probe can be heated to record the skin temperature at a steady, incremental rate of 0.6°C per second until the dog responds to the thermal stimulation or the 55°C safety cut-out, whichever comes first. This model was used to assess the baseline reproducibility and the effect of levomethadone, acepromazine and fentanyl.

**Chemical Stimulation:** Chemical stimulation involves injection of an algogenic substance into the animal tissue. These tests use intraperitoneal and intradermal injections of irritant chemicals, such as formalin, capsaicin, carrageenan, turpentine and complete Freund's adjuvant (CFA), commonly available inflammatory substances with the ability to provoke inflammatory responses and irritating body tissues. This stimulation is very slow,

progressive, of longer duration and different from electric, mechanical and thermal stimuli. The result of this test is a behavioral score rather than the threshold measured. Animal models of visceral and peritoneal pain also use algogenic agents.

In a previous study, an administration of intradermal 0.5 - 15% formalin at 0.5 - 15% on the dorsal surface of the fore paw of the rat produced painful behavior. This behavioral posture was graded as "0" for normal posture; "1" for the paw on the ground with no support to the animal; "2" for the paw unable to place on the ground; and "3" for the paw being licked, nibbled, or shaken in response to chemical irritation<sup>[112]</sup>.

The chemical nociceptive model uses the "writhing test" by injecting the algogenic substance intraperitoneally and directly into the hollow organs to produce visceral pain in rats<sup>[113,114]</sup>. This pain is characterized by whole body movements (particularly of the hind paws), abdominal contractions, twisting of the dorsoabdominal muscles, and decreased motor activity and motor incoordination. The "pain behaviour" produced by these tests is complex and biphasic, characterized by body stretching and contraction of either the flanks or the whole body in the initial phase and predominantly involves abdominal licking and nibbling in the second phase<sup>[115,116]</sup>. Similar models have been reported for bladder pain with intravesical injection of capsaicin, capsaicin-like substances<sup>[103,117-119]</sup> and turpentine as an irritant substance<sup>[120]</sup>. A model of uterine pain was also developed, where intrauterine injection of mustard oil was used as an algogenic agent<sup>[121]</sup>.

In an experimental model, the dogs under anaesthesia were given sodium urate or calcium pyrophosphate crystals in stifle joints to quantify the host response<sup>[122]</sup>. Toutain et al.<sup>[123]</sup> used Freund's adjuvant arthritis model of pain in dogs to determine the dose regimen of nimesulide, a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). In another study<sup>[124]</sup>, efficacy of low-dose ketoprofen was investigated in sodium urate crystal-induced synovitis model of arthritis. In a similar study by McCann et al.<sup>[125]</sup> a urate crystal-induced synovitis model was used to observe the *in vitro* effects and *in vivo* efficacy of a novel COX-2 inhibitor in dogs.

In summary, the above studies demonstrate the use of animal models of pain using various chemical agents in rats and dogs. The disadvantage of these models is that they may harm the animal because they have unavoidable characteristics once administered<sup>[80]</sup>. Additionally, chemical models are more invasive and less humane<sup>[80]</sup>. These models are experimental models of chronic pain. Therefore, distinction should be made from our current discussion on acute perioperative models. Detail discussion of the chronic models of pain is beyond

perioperative pain. It is worth to mention here that, the fundamental knowledge on pain studies was developed from rodent models, however, the disparity between nerve fibers composition, density of nerve fibers per skin area, and pain tolerance may lead to key differences in pain response among dogs and cats from rodents<sup>[126]</sup>.

### Surgical Models of Pain

**Ovariohysterectomy and Castration:** Over the last decade, interest in the understanding of the mechanism underlying pain for the benefit of animals has increased. For this purpose, most of the work has focused on acute pain models. Commonly used models for this were heat or pressure<sup>[127,128]</sup> and clinical pain<sup>[129]</sup>. Most acute clinical pain studies have evaluated the effects of surgical trauma on companion animals<sup>[93,94,128,130]</sup>. Among these studies, the most commonly used surgical model of pain is ovariohysterectomy. The Center for Veterinary Medicine of the US Food and Drug Administration (FDA) considered OHE a suitable model to investigate moderate pain in clinical studies of analgesia<sup>[129]</sup>. Castration and ovariohysterectomy are commonly performed elective surgical procedures in small animal practice<sup>[131]</sup>. These surgeries produce significant postoperative pain<sup>[132]</sup>. Several studies have reported ovariohysterectomy, to be a noxious procedure for bitches<sup>[129,133,134]</sup>. Traction on the mesovarium during ovariectomy is recognized as one of the most potent noxious stimuli, often eliciting pronounced autonomic and hemodynamic responses, and, in some cases, patient movement despite anesthetic depth<sup>[135,136]</sup>. The efficacy of the drug to be tested can be evaluated more reliably on these elective procedures because these surgeries are performed on healthy animals that are pain free, assuming all the postoperative pain is due to surgery<sup>[137]</sup>.

## PAIN ASSESSMENT TOOLS

Pain assessment tools can be broadly categorized based on their application in experimental or clinical settings and may be further divided into objective and subjective measures.

Objective tools include neuro-endocrine responses, heart rate (HR), blood pressure (BP), respiratory rate (RR), electroencephalography, heat and mechanical threshold testing and hand-held devices such as algometer and the von Frey device. Heart Rate, BP, RR and pupillary diameter are routinely used parameters of pain assessment intraoperatively as well as postoperatively during the recovery period and even later. Postoperatively, factors such as stress, fear, and environmental noise may also influence physiological parameters, including HR, BP, and RR, and should be considered and controlled for when

interpreting these measurements <sup>[138-140]</sup>.

Objective tools include behaviour and pain scoring scales. Objective markers like HR, BP and RR would be very useful along with behavioural markers for proper pain assessment. Pain scoring scales can be further categorised into unidimensional and multidimensional. Unidimensional scale consists of expressions like No, Mild, Moderate or Severe Pain. Examples of these include simple descriptive (SDS), Numerical Rating Scale (NRS) and Visual analogue scale (VAS). Multidimensional are subcategorised with behavioural or pictorial indicators given a particular score, these include the University of Melbourne Pain Scale, Glasgow pain scale, Colorado pain scale for canine and feline, Feline Grimace and UNESP-Botucatu MCPS. The advantage of multidimensional scales is that they allow pain measurement from more than one aspect; neither specialized skills nor experience is required to use these scales. This could be due to the pain descriptors, acquired from practicing veterinary surgeons, regularly examining dogs and cats for acute pain behavior.


Requirement of busy veterinary practice is that a pain scale should be user friendly, require less skills and knowledge for scoring. The authors' experience with the Glasgow Composite Pain Scale and, more recently, the Feline Grimace Scale has been favorable. In contrast, the Visual Analog Scale was found to be more challenging to apply consistently.

## OBJECTIVE TOOLS OF PAIN ASSESSMENT

### Neurophysiological Techniques

**Electroencephalography:** Electroencephalography (EEG) has been used as an objective tool for the investigation of pain <sup>[141]</sup>. This is a non-invasive and stress-free technique. Parameters of the EEG for nociception under anaesthesia and pain in conscious animals have received much attention. However, due to the deficiency of standard recording techniques in animals, and complexity in data analysis, the use of EEG in veterinary practice is limited <sup>[142]</sup>.

**What is Electroencephalography?** The EEG is the real-time graphical representation of the microvolt range tiny but spontaneously produced neuronal signals from the cerebral cortex through electrodes placed on different positions on the head. Neurons having an intrinsic electrical nature to produce electrical and magnetic fields. When recorded at a distance from the source, these fields are termed "far-field potentials", whereas those recorded at a short distance from the source are known as "near-field potentials". The EEG is recorded at distance from the source neurons and therefore is "far-field potential". An action



**Fig 6.** (A) Power Lab Biopotential Recordings system device (Power Lab data acquisition system, AD Instruments Ltd. Sydney, Australia). (B) Electrode indicators with channels 1 and 2

potential transmitted along the nerve fiber approaches a synapse and creates a change in the membrane potential of the postsynaptic neuron, the postsynaptic potential. These changes in the membrane potential of postsynaptic neurons are the main contributors of the EEG <sup>[143]</sup>.

**Electroencephalography Recording:** The EEG recording apparatus comprises electrodes, a signal recording amplifier and a recording system (Fig. 6). Electrodes connect with the conducting fluid of the tissue and the input circuit of the amplifier. The impedance is crucial for accurate and/or minimum loss of EEG signals. Thus, electrode-tissue impedance is maintained at a level substantially lower than the input impedance of the amplifier to ensure accurate signal acquisition <sup>[141,143,144]</sup>. Different configurations for the placement of the electrodes have been described, and several studies have reported the configuration described by Mayhew and Washbourne <sup>[145]</sup> with the positive, negative and ground electrodes as shown in Fig. 7 <sup>[142]</sup>.

**Analysis of the Electroencephalographic Data:** The analysis of EEG data is conducted offline at the end of




Fig 7. A, B, C: Three electrode configuration to record EEG electrodes in an anesthetised dog

the experiment. Fast Fourier Transformation (FFT) is a mathematical procedure to quantify data within raw EEG signals. The fast Fourier transformation system converts the raw EEG signals to different frequencies characterized by corresponding amplitudes. These EEG frequencies have been reported as delta (0.1 to 4 Hz), theta (4.1 to 8 Hz), alpha (8.1 to 12 Hz) and beta frequency [12.1 to 20 Hz] [142,143,146]. This creates a power spectrum, which is the distribution and derivation of the EEG variables of corresponding frequencies and amplitudes (Fig. 8).

**Variables of the Electroencephalography:** Total power (Ptot), Median frequency (F50 or MF) and spectral edge frequencies (SEF95%) are the variable extracted from EEG data. These are the most common variables associated with nociception in animals [142,144,146]. “Total area under the cover” is the total power. The median frequency is “the frequency below which 50% of the total power of the EEG is located”. Spectral Edge frequency 95% is “the frequency below which the 95% of the total power of the EEG is located” [144].

Arousal or desynchronization is characteristic of the brain’s response to unpleasant stimulus, typically causing increase in MF (Fig. 9) and a decrease in Ptot [93,94]. Noxious stimulus results in a change of the EEG from high amplitude low frequency (seen in anaesthesia, sedation, sleeping




Fig 8. EEG spectrum of a dog under anesthesia, showing visible effects of nociceptive stimulus (pre versus post stimulus) on various waves and heart rate




Fig 9. Median frequency of a dog under anesthesia, showing visible effects of nociceptive stimulus before and after stimulus. Note the increase in the area under the curve after stimulus

or calmness) to low amplitude high frequency waves (resembling that of awakesness or alertness); this shifting of EEG is called arousal or “desynchronization” [144]

Synchronization or paradoxical arousal is another change in EEG associated with noxiousness but is less commonly reported and is mostly described in clinical studies, which used multiple anesthetic and analgesic agents with varying noxious stimuli [147-149]. Synchronization is a shift in the EEG towards high-amplitude and low-frequency activity. Some other clinical studies were unable to demonstrate EEG changes in response to noxious stimuli [150-152]. However, current reports suggest that EEG is a robust tool for well-controlled nociceptive studies [141,142,143,146].

**Changes in EEG Spectrum During Nociceptive Studies:** It has been accepted that EEG is a direct indicator of the state of responsiveness of the central nervous system under anesthesia [94,142]. Changes in the EEG power spectrum can be used objectively to quantify nociception in horses [153,154], rats [155], deer and sheep [156,157], calves [158] and dogs [141,142]. Median frequency has been reported to be the predominant change in response to noxious stimuli [93,94,141,142]. These lines of evidence suggest that EEG can be used as an objective tool to evaluate the analgesic efficacy of drugs.

### Minimal Anesthesia Model (MAM)

Johnson and his co-workers developed a model of anesthesia to study the effects of noxious stimuli on the EEG spectrum [144]. This model was first used in horses to investigate the effects of castration on EEG [153]. In the minimal anesthesia model, animals are anesthetized to a stable plane, but they are capable of showing EEG responses to nociceptive stimulation despite being unconscious. When compared with other studies using painful methods, this model works a negative control group without compromising animal welfare/ethics. This method uses the EEG response to noxious stimulation as a technique to assess analgesia for studies of pain in applied veterinary research. This is a sensitive and quantitative technique of assessing central responses to painful stimulation [144]. A minimal anesthesia model has been used in horses [153,154], sheep [156], red deer [157], pigs [160] and dogs [93,94,141,142].

### Somatosensory Evoked Potentials

Somatosensory evoked potentials (SEPs) have been reported to evaluate the function of the nervous system. These are the electric potentials generated at various levels of the nervous system, for example peripheral nerve, plexus, nerve roots, spinal cord segments and the sensory cortex. Most commonly used nerves for the stimulation of pelvic and thoracic limbs are tibial and median nerve, respectively [161-164]. These nerves are stimulated through inserting electrodes or stainless-steel needles into subcutaneous tissue at distal end. Stimulation at proximal to targeted nerve can result in more reflex actions of muscles due to recruitment of more fibers with increased potential. This increased activity of the muscles can be avoided by stimulation of the median nerve just above the carpus and tibial nerve just above the tarsus [151]. The cathode (negative electrode) can cause depolarization of the axon membrane and should be placed 2 cm proximal to the anode (positive electrode), to avoid conduction block by anode [162,163]. Recordings of the evoked potential are shown on a computer screen; recordings and waves associated to each limb can be seen in various windows, adjustable for improved visualization. Clinically SEPs are used to evaluate the integrity of sensory pathway conductivity and may therefore be used to examine central and peripheral neurological conditions [163].

### von Frey

In electronic devices, an integrated load cell is used to measure the force applied to a rigid tip. A von Frey device consists of a tip that produces painful stimuli by gradual application of force to the skin surface. Some von Frey devices employ larger hairs to retest until the subject reacts before the hair bends, whereas fine hairs are used that bend at a maximum force. While working on quantification of pain with von Frey device on humans [80]



Fig 10. Wagner algometer FPX 25 with circular tip used in various studies of pain research in animals

scientists have diverted their attention towards developing devices which can be used at the site of pain. von Frey has been used successfully to measure mechanical nociceptive threshold testing for analgesic trials in dogs [110].

### Algometry

Schiffman et al. [165] described a pressure algometer for examining muscle tenderness in patients with myofascial pain syndrome. The use of algometers for mechanical pressure in humans led to the usage of algometers for mechanical nociceptive threshold testing of analgesic trials in dogs [61,129,166]. An algometer consists of a probe with a tip or disc, a load cell, transducer and an amplifier. It is used perpendicular to the skin on the point to be tested. Pressure is applied on the site by gradually increasing force to produce a painful stimulus (Fig. 10). The force exerted to the tip is transferred to a load cell, producing a voltage output. This voltage output is transduced, amplified, and displayed in newtons or kilograms [61,128,166,167]. These devices have the ability to activate both the A $\delta$  and C fibers, responsible for encoding clinical pain [80]. Algometry can be used in clinical settings to assess post-operative hyperalgesia and in experiments to assess the effectiveness of analgesics [168].

A variety of algometers have been used in humans [169,170] as well as animals [167,171-173] with different objectives. These studies have used various diameters of tips, such as 1 cm probe tip [67,174], 2 mm probe tip [61,132,171], and 0.5 mm probe tip [109]. Due to various tip sizes, the pressure required to initiate the response was different in these studies. For example, pressures were 1.92 N [109], 30.81 N [171], ~38 N [174,175], 38-44 N [167], and 9.94 N at the tibia [61] to provoke a response in these studies.

Regardless of the tip size, whenever an algometer is used in research, one should practice its use in order to avoid incorrect readings and then set a baseline of the particular experimental animal. Each animal would have a different baseline based on animal's pain tolerance. Before we begin to use the algometer in a clinical setting, there is a need to fix an end-point for a particular species. However, the use of an algometer is rare in clinical settings, due to the fact that behavioural and physiological parameters like HR, BP and RR can easily be applied for pain assessment. On the other hand, algometer is more frequently used in experimental models.

Fixing an end-point of a nociceptive test would be challenging experimentally because of individual or species variation. Peripheral perception may be impacted by nociceptors' distribution, blood flow, and skin thickness [126]. Therefore, to achieve the best outcomes, it is essential to assess nociceptive threshold and determine the end-point for each species and individual. These end-points could be identified through training of the animals before the experiment. Vocalization, limb withdrawal reflex with and without vocalization and guarding of the abdomen were the most common end-points in dogs [166].

Electronic von Frey and algometer have similar working principles. Unlike the von Frey device, the algometer is easy to use and consists of a single, basic handheld unit without any electrical wire or additional parallel units. It can be used easily in the clinical setting in conscious dogs. One of the disadvantages of the algometer use is the inability of the operator to apply a continuous rate of force. Threshold readings could be affected by the rate of force application, for instance, faster rates would result in higher readings [176]. This can be minimized by continuous practice [62] or using a continuous rate of application of force (CRAF) meter for accuracy [61].

### Neuro-Endocrine Responses

Endocrine response is stimulated by afferent action potential from the site of surgery. These action potentials travel along sensory nerve roots through the dorsal root of the spinal cord to the medulla to stimulate the hypothalamus. Increases in sympathetic activity and pituitary hormones are characteristic responses to surgery [177]. Norepinephrine from the presynaptic nerve terminals and catecholamines from the adrenal medulla

are released as a result of hypothalamic stimulation of the sympathetic autonomic nervous system. Hypothalamic releasing factor stimulates the anterior pituitary, causing the secretion of adrenocorticotrophic hormone (ACTH), growth hormone, prolactin, arginine vasopressin and beta-endorphin [178]. Growth hormone activates protein synthesis and prevents its breakdown, activates glycogenolysis in the liver, promotes lipolysis, and has an anti-insulin effect [177]. Arginine vasopressin, which has a major role as an antidiuretic hormone, is also released from the posterior pituitary. Corticotrophin or adrenocorticotrophic hormone acts on the adrenal cortex and increases cortisol secretion in the plasma within minutes after surgery. Both of these hormones can be measured in the plasma within minutes of surgery [177].

**Cytokines:** Surgery instigates a series of events, including inflammatory reactions and nociception. Tissue and peripheral nerve injury can result in a local inflammatory reaction. In reaction, the concentrations of various biological mediators, including substance-P, PGs, bradykinins, CGRP and cytokines, can also be elevated in the injured tissue [179], particularly pro-inflammatory cytokines [180,181]. Among various mechanisms of pain, pro-inflammatory cytokines have recently been investigated comprehensively [180,182,183].

Cytokines are small proteins secreted and released by cells. They have specific action on the interaction and communication between cells. Cytokines are produced by cells such as lymphocytes (lymphokines) and monocytes (monokines). Those produced by leukocytes act on other leukocytes (interleukin), and cytokines can also release chemokines to perform chemotactic activities. Cytokines are pleiotropic (various cell types produce the same cytokine or single cytokine acts on different cell types) as well as redundant (same functions stimulated by different cytokines) in their action. They are mostly released in a cascade where one cytokine activates its target cell to produce additional cytokines. They also have synergistic and antagonistic effects. Many cells are responsible for making cytokines, but macrophages and helper T cells are principal cells [184].

**Mechanism of Action:** Cytokines influence the intracellular modulating processes by binding its specific membrane-bound receptor. A series of phosphorylated constitutively expressed signal proteins takes place inside the cell. These phosphorylated signal proteins travel through the cytoplasm and contact the nucleus on the condition that they should have a nuclear localization sequence or bind to a protein with their compatible sequence. In the nucleus, they may affect the transcription rate or induce post-translational changes. Proteins that participate in pain are signal transducer and activator of transcription (STAT) [185], c-fos [186,187], Ras/Raf, c-Jun [186] and mitogen

activated protein kinase (MAPK) [185,188]. Interestingly, these proteins also take part in the intracellular signaling pathways of several cytokines, including IL-6 [189].

In previous studies of the cellular mechanism of inflammatory pain, it has been established that a well-defined sequential cascade of cytokines/chemokines is followed by the release of PGs and sympathetic amines [190,191]. Classical pro-inflammatory cytokines such as TNF- $\alpha$ , IL-1 $\beta$  and IL-6 play roles in pathological pain [184]. IL-1 $\beta$  and IL-6 can provoke peripheral and central sensitization, resulting in pain augmentation (hyperalgesia) [192,193]. The direct action of cytokines on nociceptive neuronal receptors and ion channels has been described in previous studies, where they regulate neuronal excitability, sensitivity to external stimuli and synaptic plasticity [194].

**Exogenous Cytokine Response:** In various experiments conducted on animal models, exogenous administration of pro-inflammatory cytokines augmented nociception [190,195-199] and increased neuronal excitability in response to noxious stimuli. In contrast, when the function of these cytokines was blocked with soluble TNF receptors, interleukin-1 receptor antagonist (IL-1ra), anti-IL-1 or anti-IL-6-neutralizing antibodies, it prevented or reversed hyperalgesia and allodynia in an animal model tested for peripheral inflammation and/or injury [182,200-203]. Patients with decreased levels of pro-inflammatory cytokines have reported less severe pain [183,204]. IL-1 and IL-6 are released in both the brain and periphery after exposure to psychological stressors [205].

**Cytokine Response to Analgesic:** Elevated central and peripheral levels of COX-2 and pro-inflammatory cytokines, especially IL-1 $\beta$ , result in the production of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) [206,207]. Pre-emptive epidural analgesia has been proven to reduce postoperative pain and decrease the production of pro-inflammatory cytokines, including IL-1 $\beta$  [183]. Pre-emptive blockade of pro-inflammatory cytokines (TNF- $\alpha$  and IL-6) increased the nociceptive threshold in experimentally induced inflammatory pain [208], reduced morphine requirement and recovery was better after cancer surgery [209]. Decreased levels of proinflammatory cytokines have been observed in patients administered with mixture of opiates and local anesthetics in the postoperative period [45].

**Role of Cytokines in Neuropathic and Inflammatory Pain:** Neuropathic pain results from injury or dysfunction of nerves. Animal models of neuropathic pain has shown involvement of several proinflammatory cytokines such as TNF- $\alpha$ , IL-1 $\beta$ , IL-6, and IL-17. These cytokines have been reported in disc herniation, sciatica, lumbar herniation, spinal cord injury and complex regional pain syndrome (CRPS) [210].

Possible mechanisms for IL-1 $\beta$ , include activation of the dorsal root ganglion neurons and increased spinal cord activity. IL-7 results an increase in the activity of transient receptor protein vanilloid 4 (TRPV4), an ion channel that has been found to mediate mechanical allodynia.

Inflammation is caused by abnormal signaling or production of pro-inflammatory cytokines such as TNF- $\alpha$  and IL-6, IL-1 [211]. These cytokines are released by immune cells after tissue injury and inflammation, sensitizing peripheral nociceptors and reducing their threshold of stimulation. This stimulation triggers the action potential travelling to dorsal horn of the spinal cord, synapsing with second order neuron. Glutamate and substance P transmit pain signals to ascending pathway, reaching higher centers of brain involved in perception. At the same time modulation of pain occurs through descending pathways, affecting intensity and perception of pain [212]. Increased sensitivity of nociceptors and exacerbated pain responses are hallmarks of inflammatory pain, indicating involvement of both peripheral and central components of pain. IL-1, and TNF- $\alpha$  play a role in hyperalgesia. Development of therapeutic agents, targeting these cytokines and their signaling pathways would significantly help alleviate pathological pain. This offers a way forward as a therapeutic approach and requires understanding interplay between cytokines and various inflammatory or neuropathic conditions

**Anti-inflammatory Cytokines:** Just as proinflammatory cytokines and their involvement in pain, nature has provided anti-inflammatory cytokines to keep balance in the immune system by suppressing inflammation and maintaining immune homeostasis. when proinflammatory cytokine levels rise in neuropathic and inflammatory pain, there is decrease in the anti-inflammatory cytokines. Lower levels of anti-inflammatory cytokines have been demonstrated in patients with chronic neuropathic pain conditions, such as complex regional pain syndrome, atypical facial pain, lower back pain, and post-herpetic neuralgia. IL-4, IL-10, IL-13, transforming growth factor beta (TGF- $\beta$ ) [210], IL-35, and IL-37 [213,214] have been reported as anti-inflammatory cytokines. interleukin-10 and transforming growth factor-beta (TGF- $\beta$ ) limit the transmission of pain.

Glatiramer acetate, an immune modulator, has been reported to decrease pain and has been correlated with increase IL-4 and IL-10. Calcineurin, uliastatin, plasmid DNA, and viral vector indirectly increase IL-10 concentrations and could be therapeutic target for neuropathic pain. Flexibilide, a substance derived from soft coral and delivery of bone marrow stromal cell into the spinal cord of mice has been reported to reduce neuropathic pain Ibutilast, a phosphodiesterase inhibitor originally developed as an asthma medication, suppressed

glial cell activation and reduced IL-1 $\beta$ , TNF- $\alpha$ , IL-6 [210]. Botulinum toxin (BoNT), the paralytic neurotoxin produced by the bacterium *Clostridium botulinum*, reduced pain related to spinal cord injury [215] and peripheral neuropathic pain [216].

IL-35 is an anti-inflammatory cytokine with potent immunosuppressive capacity (Fiore NT et al., 2024). IL-35 alleviated pain in autoimmune encephalomyelitis (EAE) mouse model of central neuropathic pain [217] and the streptozotocin rat model of diabetic neuropathy [218]. IL-37, suppresses inflammation and immune activation. Inhibits production of IL-1 $\beta$ , IL-6, TNF- $\alpha$ . This anti-inflammatory cytokine has potential therapeutic target for autoimmune diseases and chronic inflammatory conditions [219].

Currently FDA approved TNF- $\alpha$  inhibitors include infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab. These are recommended for painful disorders such as inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Canakinumab, Gevokizumab, and Anakinra, are FDA approved drug against IL-1 $\beta$ , Tocilizumab, Sarilumab, and Sirukumab against IL-6 (Low back and leg pain) and secukinumab for IL-7 and Secukinumab for IL-17. Other cytokine modulators include Emapalumab, Ruxolitinib, Tofacitinib, approved by FDA for various conditions involving pathological pain pathways [211].

**Hormones (Adrenaline, Nor-adrenaline, Endorphins, Cortisol):** Briefly, several hormonal changes linked with stimulation of the hypothalamic-pituitary-adrenal axis in response to surgical stress have been reported. Of these, adrenal corticosteroids such as cortisol, inflammatory mediators including beta-endorphins and other associated pituitary hormones have been used in previous studies of pain and associated stress assessment [82,128,130,220,221]. This method of changes in plasma concentration of hormones and cytokines is advantageous in the sense that it minimizes observer variability associated with behavioral assessment of pain and is more objective than behavioral assessment. However, there are some disadvantages and limitations [222] of this method, summarised as follows:

1. A single sample collected at a specific time point in an animal experiencing pain may not accurately reflect the level of pain present at that moment. For example, similar biomarker readings observed in control animals without pain and in animals subjected to painful stimuli may reflect the inherent variability of hormonal and cytokine responses. These variations can result from changes in plasma concentrations associated with stress or other non-nociceptive physiological processes.
2. These biomarkers lack sufficient specificity for accurate pain assessment and should therefore be interpreted

in conjunction with other validated scoring systems. However, their routine use in clinical practice is limited due to their invasive nature, associated costs, and the need for specialized analysis, and they are consequently infrequently utilized in clinical settings.

## CONCLUSIONS

It is now well established that surgical trauma results in nociception triggering a cascade of chemical reactions that take place at the primary site and throughout the central nervous system. These chemical reactions produce an “inflammatory soup” that brings changes in the central nervous system, resulting in the development of central sensitization and long-term potentiation manifested clinically as hyperalgesia and allodynia, subsequently developing into chronic pain. Nociception includes sodium and potassium channels that contribute to transduction and transmission. Excitatory neurotransmitters, including glutamate, substance P and CGRP, play key roles in modulation. Glutamate, through activation of NMDA receptors and other excitatory pathways, plays a critical role in the development of central sensitization. The use of multimodal analgesia, involving drugs with different mechanisms of action, can help attenuate these processes and improve postoperative pain management.

## DECLARATIONS

**Availability of Data and Materials:** All the data generated are included in the manuscript

**Acknowledgements:** The authors are grateful to Universiti Putra Malaysia for funding this project (GP-IPM/2020/9684 100).

**Competing of Interest:** The authors declared that there is no competing of interests.

**Declaration of Generative Artificial Intelligence (AI):** The article and/or tables and figures were not written/created by AI and AI assisted technologies.

**Author Contributions:** YMG and UK contributed to the conceptualisation and methodology of the study. UK, MWA and AS were responsible for data extraction and editing. The original draft of manuscript was written by UK. YMG and CHC validated the extracted data and tables. KAM provided academic advice and critical revision. UK, MWA and AS revised and finalised the manuscript. All authors read and approved the final version.

## REFERENCES

1. **Monteiro BP, Lascelles BDX, Murrell J, Robertson S, Steagall PVM, Wright B:** 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. *J Small Anim Pract*, 64 (4): 177-254, 2023. DOI: 10.1111/jsap.13566
2. **Monteiro BP, Steagall PV:** Chronic pain in cats: Recent advances in clinical assessment. *J Feline Med Surg*, 21 (7): 601-614, 2019. DOI: 10.1177/1098612X19856179
3. **Gaynor JS, Muir WW III:** Acute pain management: A case-based approach. In, Gaynor JS, Muir WW (Eds): *Handbook of Veterinary Pain Management*. 3<sup>rd</sup> ed., 346-380, Mosby Elsevier, St. Louis, 2014.

4. Gruen ME, Lascelles BDX, Colleran E, Gottlieb A, Johnson J, Lotsikas P, Marcellin-Little D, Wright B: 2022 AAHA pain management guidelines for dogs and cats. *J Am Anim Hosp Assoc*, 58 (2): 55-76, 2022. DOI: 10.5326/JAAHA-MS-7292
5. AAHA/AAFP Pain Management Guidelines Task Force Members, Hellyer P, Rodan I, Brunt J, Downing R, Hagedorn JE, Robertson SA: AAHA/AAFP pain management guidelines for dogs and cats. *J Feline Med Surg*, 9 (6): 466-480, 2007. DOI: 10.1016/j.jfms.2007.09.001
6. Hirose M, Okutani H, Hashimoto K, Ueki R, Shimode N, Kariya N, Takao Y, Tatara T: Intraoperative assessment of surgical stress response using nociception monitor under general anesthesia and postoperative complications: A narrative review. *J Clin Med*, 11 (20):6080, 2022. DOI: 10.3390/jcm11206080
7. Bonin EA, Lejeune N, Szymkowicz E, Bonhomme V, Martial C, Gosseries O, Laureys S, Thibaut A: Assessment and management of pain/nociception in patients with disorders of consciousness or locked-in syndrome: A narrative review. *Front Syst Neurosci*, 17:112206, 2023. DOI: 10.3389/fnsys.2023.1112206
8. Willis WD, Westlund KN: Neuroanatomy of the pain system and of the pathways that modulate pain. *J Clin Neurophysiol*, 14 (1): 2-31, 1997. DOI: 10.1097/00004691-199701000-00002
9. Dubin AE, Patapoutian A: Nociceptors: the sensors of the pain pathway. *J Clin Invest*, 120 (11): 3760-3772, 2010. DOI: 10.1172/JCI42843
10. Muir WW, III, Woolf CJ: Mechanisms of pain and their therapeutic implications. *J Am Vet Med Assoc*, 219 (10): 1346-1356, 2001. DOI: 10.2460/javma.2001.219.1346
11. Monteiro BP, Simon BT: Pain management. In: Schaer M, Gaschen F, Walton S (Eds): *Clinical Medicine of the Dog and Cat*. 4<sup>th</sup> ed., 997-1018, CRC Press, Boca Raton, 2022.
12. Kelly DJ, Ahmad M, Brull SJ: Preemptive analgesia I: physiological pathways and pharmacological modalities. *Can J Anaesth*, 48 (10): 1000-1010, 2001. DOI: 10.1007/BF03016591
13. Rexed B: The cytoarchitectonic organization of the spinal cord in the cat. *J Comp Neurol*, 96 (3): 415-495, 1952. DOI: 10.1002/cne.900960303
14. Basbaum AI, Bautista DM, Scherrer G, Julius D: Cellular and molecular mechanisms of pain. *Cell*, 139 (2): 267-284, 2009. DOI: 10.1016/j.cell.2009.09.028
15. Loveridge R, Patel S: Systemic non-opioid adjuvant analgesics: Their role in acute postoperative pain in adults. *Trends Anaesth Crit Care*, 4 (1): 10-18, 2014. DOI: 10.1016/j.tacc.2013.10.002
16. Gold MS, Gebhart GF: Nociceptor sensitization in pain pathogenesis. *Nat Med*, 16 (11): 1248-1257, 2010. DOI: 10.1038/nm.2235
17. Nikolaev Y, Cox CD, Ridone P, Rohde PR, Cordero-Morales JF, Vasquez V, Laver DR, Martinac B: Mammalian TRP ion channels are insensitive to membrane stretch. In: *Proceedings of the 64<sup>th</sup> Annual Meeting of the Biophysical Society*. 15-19 February, San Diego, California, USA, 2020.
18. Noël J, Zimmermann K, Busserolles J, Deval E, Alloui A, Diochot S, Guy N, Borsotto M, Reeh P, Eschaliier A, Lazdunski M: The mechano-activated K<sup>+</sup> channels TRAAK and TREK-1 control both warm and cold perception. *EMBO J*, 28 (9): 1308-1318, 2009. DOI: 10.1038/emboj.2009.57
19. Zimmermann K, Leffler A, Babes A, Cendan CM, Carr RW, Kobayashi J, Nau C, Wood JN, Reeh PW: Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. *Nature*, 447, 855-858, 2007. DOI: 10.1038/nature05880
20. Babos MB, Grady B, Wisnoff W, McGhee C: Pathophysiology of pain. *Dis Mon*, 59, 330-358, 2013. DOI: 10.1016/j.disamonth.2013.05.003
21. Liedtke W: TRPV4 as osmosensor: A transgenic approach. *Pflugers Arch*, 451 (1):176-180, 2005. DOI: 10.1007/s00424-005-1449-8
22. Gottlieb PA, Sachs F: Piezo1: Properties of a cation selective mechanical channel. *Channels (Austin)*, 6 (4): 214-219, 2012. DOI: 10.4161/chan.21050
23. Woo SH, Lukacs V, De Nooij JC, Zaytseva D, Criddle CR, Francisco A, Jessell TM, Lee W, Choi S: Piezo2 is the principal mechanotransduction channel for proprioception. *Nat Neurosci*, 18 (12): 1756-1762, 2015. DOI: 10.1038/nn.4162
24. Amato V, Viña E, Calavia MG, Villarreal A, Cid LP, Sepúlveda FV, González A: TRPV4 in the sensory organs of adult zebrafish. *Microsc Res Tech*, 75 (1): 89-96, 2012. DOI: 10.1002/jemt.21025
25. François A, Schüetter N, Laffray S, Sanguesa J, Pizzoccaro A, Dubel S, Mantillieri A, Nargeot J, Noel J, Wood JN, Moqrich A: The low-threshold calcium channel Cav3.2 determines low-threshold mechanoreceptor function. *Cell Rep*, 10 (3): 370-382, 2015. DOI: 10.1016/j.celrep.2014.12.055
26. Maingret F, Fosset M, Lesage F, Lazdunski M, Honoré E: TRAAK is a mammalian neuronal mechano-gated K<sup>+</sup> channel. *J Biol Chem*, 274 (3): 1381-1387, 1999. DOI: 10.1074/jbc.274.3.1381
27. Anand S, Rajagopal S: A comprehensive review on the regulatory action of TRP channels: A potential therapeutic target for nociceptive pain. *Neurosci Insights*, 18:26331055231220340, 2023. DOI: 10.1177/26331055231220340
28. Nazıroğlu M, Braidy N: Thermo-sensitive TRP channels: Novel targets for treating chemotherapy-induced peripheral pain. *Front Physiol*, 8:1040, 2017. DOI: 10.3389/fphys.2017.01040
29. Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH, Wood JN: Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. *Proc Natl Acad Sci USA*, 101, 12706-12711, 2004. DOI: 10.1073/pnas.0404915101
30. Yoshimura M, Furue H: Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. *J Pharmacol Sci* 101:107-117, 2006. DOI: 10.1254/jphs.CRJ06008X
31. Tracey I, Mantyh PW: The cerebral signature for pain perception and its modulation. *Neuron*, 55, 377-391, 2007. DOI: 10.1016/j.neuron.2007.07.012
32. Giordano J: The neurobiology of nociceptive and anti-nociceptive systems. *Pain Physician*, 8, 277-290, 2005.
33. Fields HL, Basbaum AI: Central nervous system mechanisms of pain modulation. In: Wall PD, Melzack R (Eds): *Textbook of Pain*. 4<sup>th</sup> ed., 309-330, Churchill Livingstone, Edinburgh, 1999.
34. Lamont LA: Multimodal pain management in veterinary medicine: The physiologic basis of pharmacologic therapies. *Vet Clin North Am Small Anim Pract*, 38, 1173-1186, 2008. DOI: 10.1016/j.cvs.2008.06.005
35. Treede R-D, Kenshalo DR, Gracely RH, Jones AKP: The cortical representation of pain. *Pain*, 79, 105-111, 1999. DOI: 10.1016/S0304-3959(98)00184-5
36. Luo Z, Yu M, Smith SD, Kritzer M, Du C, Ma Y, Cosgrove KP, Zhang N, Zhang X: The effect of intravenous lidocaine on brain activation during non-noxious and acute noxious stimulation of the forepaw: A functional magnetic resonance imaging study in the rat. *Anesth Analg*, 108, 334-344, 2009. DOI: 10.1213/ane.0b013e31818e0d34
37. Melzack R, Casey KL: Sensory, motivational, and central control determinants of pain: A new conceptual model in pain. In: Kenshalo DR Jr (Ed): *The Skin Senses*. 423-443, Charles C Thomas, Springfield, 1968.
38. Bowsher D: Role of the reticular formation in responses to noxious stimulation. *Pain*, 2, 361-378, 1976. DOI: 10.1016/0304-3959(76)90079-8
39. D'Mello R, Dickenson AH: Spinal cord mechanisms of pain. *Br J Anaesth*, 101, 8-16, 2008. DOI: 10.1093/bja/aen088
40. Gili T, Saxena N, Diukova A, Murphy K, Hall JE, Wise RG: The thalamus and brainstem act as key hubs in alterations of human brain network connectivity induced by mild propofol sedation. *J Neurosci*, 33 (9): 4024-4031, 2013. DOI: 10.1523/JNEUROSCI.3480-12.2013
41. Huang Z, Mashour GA, Hudetz AG: Propofol disrupts the functional core-matrix architecture of the thalamus in humans. *Nat Commun*, 15 (1):7496, 2024. DOI: 10.1038/s41467-024-51837-1
42. Kantonen O, Laaksonen L, Alkire M, Scheinin A, Långsjö J, Kallionpää RE, Maksimow A, Laitio R, Kaisti K, Aantaa R, Jääskeläinen SK, Scheinin H: Decreased thalamic activity is a

- correlate for disconnectedness during anesthesia with propofol, dexmedetomidine and sevoflurane but not S-ketamine. *J Neurosci*, 43 (26): 4884-4895, 2023. DOI: 10.1523/JNEUROSCI.2339-22.2023
43. **Steagall PV, Bustamante H, Johnson CB, Turner PV:** Pain management in farm animals: Focus on cattle, sheep and pigs. *Animals (Basel)*, 11 (6):1483, 2021. DOI: 10.3390/ani11061483
  44. **Leone CM, Lenoir C, van den Broeke EN:** Assessing signs of central sensitization: A critical review of physiological measures in experimentally induced secondary hyperalgesia. *Eur J Pain*, 28 (1): 20-39, 2024. DOI: 10.1002/ejp.4733
  45. **Schaible HG, Ebersberger A, Natura G:** Update on peripheral mechanisms of pain: Beyond prostaglandins and cytokines. *Arthritis Res Ther*, 13:210, 2011. DOI: 10.1186/ar3305
  46. **Marek-Jozefowicz L, Nedoszytko B, Grochocka M, Żmijewski MA, Czajkowski R, Cudała WJ, Słominski AT:** Molecular mechanisms of neurogenic inflammation of the skin. *Int J Mol Sci*, 24 (5):5001, 2023. DOI: 10.3390/ijms24055001
  47. **Gupta K, Harvima IT:** Mast cell-neural interactions contribute to pain and itch. *Immunol Rev*, 282 (1):168-187, 2018. DOI: 10.1111/imr.12622
  48. **Pinho-Ribeiro FA, Verri WA, Chiu IM:** Nociceptor sensory neuron-immune interactions in pain and inflammation. *Trends Immunol*, 38 (1): 5-19, 2017. DOI: 10.1016/j.it.2016.10.001
  49. **Woolf CJ:** Somatic pain: Pathogenesis and prevention. *Br J Anaesth*, 75, 169-176, 1995. DOI: 10.1093/bja/75.2.169
  50. **Cousins MJ, Power I:** Acute and postoperative pain. In, Wall PD, Melzack R (Eds): *Textbook of Pain*. 4<sup>th</sup> ed., 447-491, Churchill Livingstone, London, 1999.
  51. **Klede M, Handwerker HO, Schmelz M:** Central origin of secondary mechanical hyperalgesia. *J Neurophysiol*, 90, 353-359, 2003. DOI: 10.1152/jn.01136.2002
  52. **Woolf CJ:** Pain: Moving from symptom control toward mechanism-specific pharmacologic management. *Ann Intern Med*, 140, 441-451, 2004. DOI: 10.7326/0003-4819-140-8-200404200-00010
  53. **Petersen-Zeitz KR, Basbaum AI:** Second messengers, the substantia gelatinosa and injury-induced persistent pain. *Pain*, 82 (Suppl. 1): S5-S12, 1999. DOI: 10.1016/S0304-3959(99)00132-3
  54. **Woolf CJ, Chong MS:** Preemptive analgesia-treating postoperative pain by preventing the establishment of central sensitization. *Anesth Analg*, 77, 362-379, 1993. DOI: 10.1213/0000539-199377020-00026
  55. **Takeda M, Takahashi M, Matsumoto S:** Contribution of the activation of satellite glia in sensory ganglia to pathological pain. *Neurosci Biobehav Rev*, 33, 784-792, 2009. DOI: 10.1016/j.neubiorev.2008.12.005
  56. **Verri WA, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH:** Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development? *Pharmacol Ther*, 112, 116-138, 2006. DOI: 10.1016/j.pharmthera.2006.04.001
  57. **Watkins LR, Hutchinson MR, Milligan ED, Maier SF:** "Listening" and "talking" to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids. *Brain Res Rev*, 56, 148-169, 2007. DOI: 10.1016/j.brainresrev.2007.06.006
  58. **Treede R-D, Meyer RA, Raja SN, Campbell JN:** Peripheral and central mechanisms of cutaneous hyperalgesia. *Prog Neurobiol*, 38, 397-421, 1992. DOI: 10.1016/0301-0082(92)90027-C
  59. **Woolf CJ:** Evidence for a central component of post-injury pain hypersensitivity. *Nature*, 306, 686-688, 1983. DOI: 10.1038/306686a0
  60. **Lascelles BDX, Waterman AE, Cripps PJ, Livingston A, Henderson G:** Central sensitization as a result of surgical pain: Investigation of the pre-emptive value of pethidine for ovariectomy in the rat. *Pain*, 62, 201-212, 1995. DOI: 10.1016/0304-3959(94)00266-H
  61. **Lascelles BDX, Cripps PJ, Jones A, Waterman-Pearson AE:** Post-operative central hypersensitivity and pain: The pre-emptive value of pethidine for ovariectomy. *Pain*, 73, 461-471, 1997. DOI: 10.1016/S0304-3959(97)00141-3
  62. **Slingsby LS, Waterman-Pearson AE:** The post-operative analgesic effects of ketamine after canine ovariohysterectomy: A comparison between pre- or post-operative administration. *Res Vet Sci*, 69, 147-152, 2000. DOI: 10.1053/rvsc.2000.0406
  63. **Ruscheweyh R, Wilder-Smith O, Drdla R, Liu XG, Sandkühler J:** Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. *Mol Pain*, 7:20, 2011. DOI: 10.1186/1744-8069-7-20
  64. **Ji R-R, Nackley A, Huh Y, Terrando N, Maixner W:** Neuroinflammation and central sensitization in chronic and widespread pain. *Anesthesiology*, 129, 343-366, 2018. DOI: 10.1097/ALN.0000000000002130
  65. **Hartmann B, Ahmadi S, Heppenstall PA, Lewin GR, Schott C, Borchardt T, Lewin GR:** The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. *Neuron*, 44, 637-650, 2004. DOI: 10.1016/j.neuron.2004.10.029
  66. **Drdla R, Sandkühler J:** Long-term potentiation at C-fibre synapses by low-level presynaptic activity *in vivo*. *Mol Pain*, 4:18, 2008. DOI: 10.1186/1744-8069-4-18
  67. **Azkue JJ, Liu XG, Zimmermann M, Sandkühler J:** Induction of long-term potentiation of C fibre-evoked spinal field potentials requires recruitment of group I, but not group II/III metabotropic glutamate receptors. *Pain* 106:373-379, 2003. DOI: 10.1016/j.pain.2003.08.007
  68. **Liu XG, Sandkühler J:** Characterization of long-term potentiation of C-fiber-evoked potentials in spinal dorsal horn of adult rat: Essential role of NK1 and NK2 receptors. *J Neurophysiol*, 78, 1973-1982, 1997. DOI: 10.1152/jn.1997.78.4.1973
  69. **Liu X-G, Sandkühler J:** Long-term potentiation of C-fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N-methyl-D-aspartic acid receptor blockage. *Neurosci Lett*, 191, 43-46, 1995. DOI: 10.1016/0304-3940(95)11553-0
  70. **Ikeda H, Heinke B, Ruscheweyh R, Sandkühler J:** Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia. *Science*, 299, 1237-1240, 2003. DOI: 10.1126/science.1080659
  71. **Ikeda H, Stark J, Fischer H, Wagner M, Drdla R, Jäger T, Sandkühler J:** Synaptic amplifier of inflammatory pain in the spinal dorsal horn. *Science*, 312, 1659-1662, 2006. DOI: 10.1126/science.1127233
  72. **Lieberman DN, Mody I:** Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. *J Neurophysiol*, 80, 113-119, 1998. DOI: 10.1152/jn.1998.80.1.113
  73. **Yang HW, Hu XD, Zhang H-M, Xin WJ, Li MT, Zhang T, Zhou LJ, Liu XG:** Roles of CaMKII, PKA, and PKC in the induction and maintenance of LTP of C-fiber-evoked field potentials in rat spinal dorsal horn. *J Neurophysiol*, 91, 1122-1133, 2004. DOI: 10.1152/jn.00735.2003
  74. **Zhang XC, Zhang YQ, Zhao ZQ:** Involvement of nitric oxide in long-term potentiation of spinal nociceptive responses in rats. *Neuroreport*, 16, 1197-1201, 2005. DOI: 10.1097/00001756-200508010-00013
  75. **Wei F, Vadakkan KI, Toyoda H, Wu LJ, Zhao MG, Xu H, Shum FW, Jia YH, Zhuo M:** Calcium calmodulin-stimulated adenylyl cyclases contribute to activation of extracellular signal-regulated kinase in spinal dorsal horn neurons in adult rats and mice. *J Neurosci* 26:851-861, 2006. DOI: 10.1523/JNEUROSCI.3292-05.2006
  76. **Xin WJ, Gong QJ, Xu JT, Yang HW, Zang Y, Zhang T, Li YY, Liu XG:** Role of phosphorylation of ERK in induction and maintenance of LTP of the C-fiber evoked field potentials in spinal dorsal horn. *J Neurosci Res* 84:934-943, 2006. DOI: 10.1002/jnr.21013
  77. **Latremoliere A, Woolf CJ:** Central sensitization: A generator of pain hypersensitivity by central neural plasticity. *J Pain* 10:895-926, 2009. DOI: 10.1016/j.jpain.2009.06.012
  78. **Li XH, Miao HH, Zhuo M:** NMDA receptor dependent long-term potentiation in chronic pain. *Neurochem Res*, 44, 531-538, 2019. DOI: 10.1007/s11064-018-2614-8

79. **Bliss TV, Cooke SF:** Long-term potentiation and long-term depression: A clinical perspective. *Clinics (Sao Paulo)*, 66, 3-17, 2011. DOI: 10.1590/S1807-59322011001300002
80. **Le Bars D, Gozariu M, Cadden SW:** Animal models of nociception. *Pharmacol Rev*, 53, 597-652, 2001.
81. **Lascelles BD, Butterworth S, Waterman AE:** Postoperative analgesic and sedative effects of carprofen and pethidine in dogs. *Vet Rec*, 134, 187-191, 1994. DOI: 10.1136/vr.134.8.187
82. **Mellor DJ, Stafford KJ, Todd SE, Lowe TE, Gregory NG, Bruce RA, Ward RN:** A comparison of catecholamine and cortisol responses of young lambs and calves to painful husbandry procedures. *Aust Vet J*, 80, 228-233, 2002. DOI: 10.1111/j.1751-0813.2002.tb10820.x
83. **Greene SA, Moore MP, Keegan RD, Gallagher LV, Rosenthal JC:** Quantitative electroencephalography for monitoring responses to noxious electrical stimulation in dogs anesthetized with halothane or with halothane and morphine. In, **Poznak AV** (Ed): Pain Measurement in Man and Animals. 459-465, Churchill Livingstone, New York, 1992.
84. **Gregory NS, Harris AL, Robinson CR, Dougherty PM, Fuchs PN, Sluka KA:** An overview of animal models of pain: Disease models and outcome measures. *J Pain*, 14 (11): 1255-1269, 2013. DOI: 10.1016/j.jpain.2013.06.008
85. **Sang CN, Max MB, Gracely RH:** Stability and reliability of detection thresholds for human A-beta and A-delta sensory afferents determined by cutaneous electrical stimulation. *J Pain Symptom Manag*, 25 (1): 64-73, 2003. DOI: 10.1016/s0885-3924(02)00541-9
86. **Handwerker HO, Kobal G:** Psychophysiology of experimentally induced pain. *Physiol Rev*, 73, 639-671, 1993. DOI: 10.1152/physrev.1993.73.3.639
87. **Quandt JE, Raffe MR, Reeh E, Wyatt R:** Evaluation of a microstrain gauge algometer for quantitative measurement of nociception in the dog. *J Vet Pharmacol Ther*, 17, 399-402, 1994. DOI: 10.1111/j.1365-2885.1994.tb00268.x
88. **Valverde A, Morey TE, Hernández J, Davies W:** Validation of several types of noxious stimuli for use in determining the minimum alveolar concentration for inhalation anesthetics in dogs and rabbits. *Am J Vet Res*, 64, 957-962, 2003. DOI: 10.2460/ajvr.2003.64.957
89. **Niv D, Whitwam JG, Loh L:** Depression of nociceptive sympathetic reflexes by the intrathecal administration of midazolam. *Br J Anaesth*, 55, 541-547, 1983. DOI: 10.1093/bja/55.6.541
90. **Wang C, Knowles MG, Chakrabarti MK, Whitwam JG:** Clonidine has comparable effects on spontaneous sympathetic activity and afferent A $\delta$ - and C-fiber-mediated somatosympathetic reflexes in dogs. *Anesthesiology*, 81, 710-717, 1994. DOI: 10.1097/00000542-199409000-00025
91. **Brown DC, Bernier N, Shofer F, Steinberg SA, Perkowski SZ:** Use of noninvasive dental dolorimetry to evaluate analgesic effects of intravenous and intrathecal administration of morphine in anesthetized dogs. *Am J Vet Res*, 63, 1349-1353, 2002. DOI: 10.2460/ajvr.2002.63.1349
92. **Bergadano A, Andersen OK, Arendt-Nielsen L, Theurillat R, Thormann W, Spadavecchia C:** Plasma levels of a low-dose constant-rate infusion of ketamine and its effect on single and repeated nociceptive stimuli in conscious dogs. *Vet J*, 182, 252-260, 2009. DOI: 10.1016/j.tvjl.2008.06.003
93. **Kongara K, Chambers JP, Johnson CB:** Electroencephalographic responses of tramadol, parecoxib and morphine to acute noxious electrical stimulation in anaesthetized dogs. *Res Vet Sci*, 88, 127-133, 2010. DOI: 10.1016/j.rvsc.2009.05.012
94. **Kaka U, Hui CC, Meng GY, Fakurazi S, Kaka A, Behan AA, Ebrahimi M:** Electroencephalographic changes associated with antinociceptive actions of lidocaine, ketamine, meloxicam, and morphine administration in minimally anaesthetized dogs. *Biomed Res Int*, 2015:Article ID:875307, 2015. DOI: 10.1155/2015/305367
95. **Ness TJ, Gebhart GF:** Colorectal distension as a noxious visceral stimulus: Physiologic and pharmacologic characterization of pseudodiffusive reflexes in the rat. *Brain Res*, 450, 153-169, 1988. DOI: 10.1016/0006-8993(88)91555-7
96. **Rouzade G, Fioramonti J, Bueno L:** A model for evaluation of gastric sensitivity in awake rats. *Neurogastroenterol Motil*, 10, 157-163, 1998. DOI: 10.1046/j.1365-2982.1998.00091.x
97. **Colburn RW, Coombs DW, Degnan CC, Rogers LL:** Mechanical visceral pain model: Chronic intermittent intestinal distention in the rat. *Physiol Behav*, 45, 191-197, 1989. DOI: 10.1016/0031-9384(89)90184-4
98. **DeLeo JA, Colburn RW, Coombs DW, Ellis MA:** The differentiation of NSAIDs and prostaglandin action using a mechanical visceral pain model in the rat. *Pharmacol Biochem Behav*, 33, 253-255, 1989. DOI: 10.1016/0091-3057(89)90458-9
99. **Jensen FM, Dahl JB, Frigast C:** Direct spinal effect of intrathecal acetaminophen on visceral noxious stimulation in rabbits. *Acta Anaesthesiol Scand*, 36, 837-841, 1992. DOI: 10.1111/j.1399-6576.1992.tb03574.x
100. **Crawford ME, Jensen FM, Toftdahl DB, Madsen JB:** Direct spinal effect of intrathecal and extradural midazolam on visceral noxious stimulation in rabbits. *Br J Anaesth*, 70, 642-646, 1993. DOI: 10.1093/bja/70.6.642
101. **Houghton KJ, Rech RH, Sawyer DC, Durham RA, Adams T, Langham MA, Rech RH:** Dose-response of intravenous butorphanol to increase visceral nociceptive threshold in dogs. *Exp Biol Med*, 197, 290-296, 1991. DOI: 10.3181/00379727-197-43258
102. **Martin WR, Eades CG, Fraser HF, Wikler A:** Use of hindlimb reflexes of the chronic spinal dog for comparing analgesics. *J Pharmacol Exp Ther*, 144, 8-11, 1964. DOI: 10.1016/S0022-3565(25)26749-0
103. **Martin WR, Eades CG, Thompson WO, Thompson JA, Flanary HG:** Morphine physical dependence in the dog. *J Pharmacol Exp Ther*, 189, 759-771, 1974. DOI: 10.1016/S0022-3565(25)29884-6
104. **Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE:** The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. *J Pharmacol Exp Ther*, 197, 517-532, 1976. DOI: 10.1016/S0022-3565(25)30536-7
105. **Hamlin RL, Bednarski LS, Schuler CJ, Weldy PL, Cohen RB:** Method of objective assessment of analgesia in the dog. *J Vet Pharmacol Ther*, 11, 215-220, 1988. DOI: 10.1111/j.1365-2885.1988.tb00144.x
106. **Atkins CJ, Zielinski A, Klinkhoff AV, Chalmers A, Wade J, Williams D, Russell AS:** An electronic method for measuring joint tenderness in rheumatoid arthritis. *Arthritis Rheum*, 35, 407-410, 1992. DOI: 10.1002/art.1780350408
107. **Bendtsen L, Jensen R, Jensen NK, Olesen J:** Muscle palpation with controlled finger pressure: New equipment for the study of tender myofascial tissues. *Pain*, 59, 235-239, 1994. DOI: 10.1016/0304-3959(94)90076-0
108. **Barnhart MD, Hubbell JAE, Muir WW, Sams RA, Bednarski RM:** Pharmacokinetics, pharmacodynamics, and analgesic effects of morphine after rectal, intramuscular, and intravenous administration in dogs. *Am J Vet Res*, 61, 24-28, 2000. DOI: 10.2460/ajvr.2000.61.24
109. **KuKanich B, Lascelles BDX, Papich MG:** Assessment of a von Frey device for evaluation of the antinociceptive effects of morphine and its application in pharmacodynamic modeling of morphine in dogs. *Am J Vet Res*, 66, 1616-1622, 2005. DOI: 10.2460/ajvr.2005.66.1616
110. **Hoffmann MV, Kästner SBR, Kietzmann M, Kramer S:** Contact heat thermal threshold testing in beagle dogs: Baseline reproducibility and the effect of acepromazine, levomeperidone and fentanyl. *BMC Vet Res*, 8:206, 2012. DOI: 10.1186/1746-6148-8-206
111. **Dixon MJ, Robertson SA, Taylor PM:** A thermal threshold testing device for evaluation of analgesics in cats. *Res Vet Sci*, 72, 205-210, 2002. DOI: 10.1053/rvsc.2001.0543
112. **Dubuisson D, Dennis SG:** The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. *Pain*, 4, 161-174, 1977. DOI: 10.1016/0304-3959(77)90130-0
113. **Vyklicky L:** Techniques for the study of pain in animals. In, **Bonica JJ, Liebeskind JC, Albe-Fessard DG** (Eds): Advances in Pain Research and Therapy. Vol. 3, 727-745, Raven Press, New York, 1979.

114. **Hammond DL**: Inference of pain and its modulation from simple behaviors. In, Chapman CR, Loeser JD (Eds): *Advances in Pain Research and Therapy*. Vol. 12, 69-91, Raven Press, New York, 1989.
115. **Miampamba M, Chéry-Croze S, Gorry F, Berger F, Chayvialle JA**: Inflammation of the colonic wall induced by formalin as a model of acute visceral pain. *Pain*, 57, 327-334, 1994. DOI: 10.1016/0304-3959(94)90008-6
116. **Botella A, Fioramonti J, Eeckhout C, Bueno L**: Intracolonic glycerol induces abdominal contractions in rats: Role of 5-HT<sub>3</sub> receptors. *Fundam Clin Pharmacol*, 12, 619-623, 1998. DOI: 10.1111/j.1472-8206.1998.tb00995.x
117. **Craft RM, Carlisi VJ, Mattia A, Herman RM, Porreca F**: Behavioral characterization of the excitatory and desensitizing effects of intravesical capsaicin and resiniferatoxin in the rat. *Pain*, 55, 205-215, 1993. DOI: 10.1016/0304-3959(93)90149-J
118. **Craft RM, Henley SR, Haaseth RC, Hrubby VJ, Porreca F**: Opioid antinociception in a rat model of visceral pain: Systemic versus local drug administration. *J Pharmacol Exp Ther*, 275, 1535-1542, 1995. DOI: 10.1016/S0022-3565(25)12215-5
119. **Pandita RK, Persson K, Andersson KE**: Capsaicin-induced bladder overactivity and nociceptive behaviour in conscious rats: Involvement of spinal nitric oxide. *J Auton Nerv Syst*, 67, 184-191, 1997. DOI: 10.1016/S0165-1838(97)00116-1
120. **Jaggar SI, Habib S, Rice ASC**: The modulatory effects of bradykinin B1 and B2 receptor antagonists upon viscerovisceral hyper-reflexia in a rat model of visceral hyperalgesia. *Pain*, 75, 169-176, 1998. DOI: 10.1016/S0304-3959(97)00217-0
121. **Wesselmann U, Czakanski PP, Affaitati G, Giamberardino MA**: Uterine inflammation as a noxious visceral stimulus: Behavioral characterization in the rat. *Neurosci Lett*, 246, 73-76, 1998. DOI: 10.1016/S0304-3940(98)00234-1
122. **McCarty DJ, Phelps P, Pyenson J**: Crystal-induced inflammation in canine joints. I. An experimental model with quantification of the host response. *J Exp Med*, 124, 99-114, 1966. DOI: 10.1084/jem.124.1.99
123. **Toutain PL, Cester CC, Haak T, Laroute V**: A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: The case of nimesulide, a COX-2 selective nonsteroidal anti-inflammatory drug in the dog. *J Vet Pharmacol Ther*, 24, 43-55, 2001. DOI: 10.1046/j.1365-2885.2001.00304.x
124. **Hazewinkel HAW, van den Brom WE, Theijse LFH, Pollmeier M, Hanson PD**: Reduced dosage of ketoprofen for the short-term and long-term treatment of joint pain in dogs. *Vet Rec*, 152, 11-14, 2003. DOI: 10.1136/vr.152.1.11
125. **McCann ME, Donald R, Zhang D, Brideau C, Black WC, Hanson PD, Borer-Weir K**: *In vitro* effects and *in vivo* efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. *Am J Vet Res*, 65, 503-512, 2004. DOI: 10.2460/ajvr.2004.65.503
126. **Monteiro-Riviere NA, Bristol DG, Manning TO, Rogers RA, Riviere JE**: Interspecies and interregional analysis of the comparative histologic thickness and laser Doppler blood flow measurements at five cutaneous sites in nine species. *J Invest Dermatol*, 95, 582-586, 1990. DOI: 10.1111/1523-1747.ep12505567
127. **Jiwlawat S, Durongphongtorn S**: The antinociceptive effects of tramadol on the thermal threshold response in cats. *Thai J Vet Med*, 41 (2): 171-177, 2011. DOI: 10.56808/2985-1130.2293
128. **Buhari S, Hashim K, Yong Meng G, Mustapha NM, Gan SH**: Subcutaneous administration of tramadol after elective surgery is as effective as intravenous administration in relieving acute pain and inflammation in dogs. *Sci W J*, 2012:564939, 2012. DOI: 10.1100/2012/564939
129. **Hansen BD**: Assessment of pain in dogs: Veterinary clinical studies. *ILAR J*, 44, 197-205, 2003. DOI: 10.1093/ilar.44.3.197
130. **Tsai TY, Chang SK, Chou PY, Yeh LS**: Comparison of postoperative effects between lidocaine infusion, meloxicam, and their combination in dogs undergoing ovariohysterectomy. *Vet Anaesth Analg*, 40, 615-622, 2013. DOI: 10.1111/vaa.12064
131. **Gassel AD, Tobias KM, Egger CM, Rohrbach BW**: Comparison of oral and subcutaneous administration of buprenorphine and meloxicam for preemptive analgesia in cats undergoing ovariohysterectomy. *J Am Vet Med Assoc*, 227, 1937-1944, 2005. DOI: 10.2460/javma.2005.227.1937
132. **Lascelles BD, Cripps PJ, Jones A, Waterman-Pearson AE**: Efficacy and kinetics of carprofen, administered preoperatively or postoperatively, for the prevention of pain in dogs undergoing ovariohysterectomy. *Vet Surg*, 27, 568-582, 1998. DOI: 10.1111/j.1532-950X.1998.tb00533.x
133. **Fox SM, Mellor DJ, Firth EC, Hodge H, Lawoko CRO**: Changes in plasma cortisol concentrations before, during and after analgesia, anaesthesia and anaesthesia plus ovariohysterectomy in bitches. *Res Vet Sci*, 57, 110-118, 1994. DOI: 10.1016/0034-5288(94)90091-4
134. **Fox SM, Mellor DJ, Lawoko CRO, Hodge H, Firth EC**: Changes in plasma cortisol concentrations in bitches in response to different combinations of halothane and butorphanol, with or without ovariohysterectomy. *Res Vet Sci*, 65, 125-133, 1998. DOI: 10.1016/S0034-5288(98)90163-1
135. **Firth AM, Haldane SL**: Development of a scale to evaluate postoperative pain in dogs. *J Am Vet Med Assoc*, 214, 651-659, 1999. DOI: 10.2460/javma.1999.214.05.651
136. **Boscan P, Monnet E, Mama K, Twedt DC, Congdon J, Eickhoff JC, Lascelles BDX**: A dog model to study ovary, ovarian ligament and visceral pain. *Vet Anaesth Analg*, 38, 260-266, 2011. DOI: 10.1111/j.1467-2995.2011.00611.x
137. **Slingsby LS, Taylor PM, Waterman-Pearson AE**: Effects of two doses of buprenorphine four or six hours apart on nociceptive thresholds, pain and sedation in dogs after castration. *Vet Rec*, 159, 705-711, 2006. DOI: 10.1136/vr.159.21.705
138. **Epstein ME, Rodan I, Griffenhagen G, Kadrlík J, Petty MC, Robertson SA, Simpson W**: 2015 AAHA/AAFP pain management guidelines for dogs and cats. *J Feline Med Surg*, 17, 251-272, 2015. DOI: 10.1177/1098612X15572062
139. **Cambridge AJ, Tobias KM, Newberry RC, Temple W**: Subjective and objective measurements of postoperative pain in cats. *J Am Vet Med Assoc*, 217, 685-690, 2000. DOI: 10.2460/javma.2000.217.685
140. **Franzini de Souza CC, Dias DPM, Souza RN, Salgado BS, Carreira L, Molento CFM**: Use of behavioural and physiological responses for scoring sound sensitivity in dogs. *PLoS One*, 13:e0200618, 2018. DOI: 10.1371/journal.pone.0200618
141. **Karna SR, Chambers P, Johnson CB, Singh P, Stewart LA, Lopez-Villalobos N, Kongara K**: Effect of combinations of morphine, dexmedetomidine and maropitant on the electroencephalogram in response to acute electrical stimulation in anaesthetized dogs. *J Vet Pharmacol Ther*, 43 (6): 538-546, 2020. DOI: 10.1111/jvp.12879
142. **Kaka U, Goh YM, Chean LW, Chen HC**: Electroencephalographic changes associated with non-invasive nociceptive stimulus in minimally anaesthetized dogs. *Pol J Vet Sci*, 19, 675-683, 2016. DOI: 10.1515/pjvs-2016-0086
143. **Kumar P, Abubakar AA, Adewale MA, Hayat MN, Adamu G, Ajat M, Sazili AQ**: Electroencephalogram, creatine kinase, and lactate dehydrogenase responses during preslaughter handling in goats handled by trained and untrained handlers. *J Indones Trop Anim Agric*, 49 (3): 215-223, 2024. DOI: 10.14710/jitaa.49.3.215-223
144. **Murrell JC, Johnson CB**: Neurophysiological techniques to assess pain in animals. *J Vet Pharmacol Ther*, 29, 325-335, 2006. DOI: 10.1111/j.1365-2885.2006.00758.x
145. **Mayhew IG, Washbourne JR**: A method of assessing auditory and brainstem function in horses. *Br Vet J*, 146, 509-518, 1990. DOI: 10.1016/0007-1935(90)90054-7
146. **Kongara K, Chambers JP, Johnson CB**: Effects of tramadol, morphine or their combination in dogs undergoing ovariohysterectomy on peri-operative electroencephalographic responses and post-operative pain. *NZ Vet J*, 60, 129-135, 2012. DOI: 10.1080/00480169.2011.641156
147. **Kochs E, Bischoff P, Pichlmeier U, Am Esch JS**: Surgical stimulation induces changes in brain electrical activity during isoflurane/nitrous oxide anesthesia. *Anesthesiology*, 80, 1026-1034, 1994. DOI: 10.1097/00000542-199405000-00012

148. **Kiyama S, Takeda J:** Effect of extradural analgesia on the paradoxical arousal response of the electroencephalogram. *Br J Anaesth*, 79, 750-753, 1997. DOI: 10.1093/bja/79.6.750
149. **Kiyama S, Tsuzaki K:** Processed electroencephalogram during combined extradural and general anaesthesia. *Br J Anaesth*, 78, 751-753, 1997. DOI: 10.1093/bja/78.6.751
150. **White PF, Boyle WA:** Relationship between hemodynamic and electroencephalographic changes during general anesthesia. *Anesth Analg*, 68, 177-181, 1989. DOI: 10.1213/00000539-198902000-00020
151. **Dwyer RC, Rampil IJ, Eger EI, Bennett HL:** The electroencephalogram does not predict depth of isoflurane anesthesia. *Anesthesiology*, 81, 403-409, 1994. DOI: 10.1097/00000542-199408000-00019
152. **Schraag S, Mohl U, Bothner U, Georgieff M:** Clinical utility of EEG parameters to predict loss of consciousness and response to skin incision during total intravenous anaesthesia. *Anaesthesia*, 53, 320-325, 1998. DOI: 10.1046/j.1365-2044.1998.00311.x
153. **Murrell JC, Johnson CB, White KL, Taylor PM, Haberham ZL, Waterman-Pearson AE:** Changes in the EEG during castration in horses and ponies anaesthetized with halothane. *Vet Anaesth Analg*, 30, 138-146, 2003. DOI: 10.1046/j.1467-2995.2003.00138.x
154. **Grint NJ, Johnson CB, Clutton RE, Whay HR, Murrell JC:** Spontaneous electroencephalographic changes in a castration model as an indicator of nociception: A comparison between donkeys and ponies. *Equine Vet J*, 47, 36-42, 2015. DOI: 10.1111/evj.12250
155. **Murrell JC, Mitchinson SL, Waters D, Johnson CB:** Comparative effect of thermal, mechanical, and electrical noxious stimuli on the electroencephalogram of the rat. *Br J Anaesth*, 98, 366-371, 2007. DOI: 10.1093/bja/ael377
156. **Johnson CB, Stafford KJ, Sylvester SP, Ward RN, Mitchinson S, Mellor DJ:** Effects of age on the electroencephalographic response to castration in lambs anaesthetised using halothane in oxygen. *N Z Vet J*, 53, 433-437, 2005. DOI: 10.1080/00480169.2005.36589
157. **Johnson CB, Wilson PR, Woodbury MR, Caulkett NA:** Comparison of analgesic techniques for antler removal in halothane-anaesthetized red deer (*Cervus elaphus*): Electroencephalographic responses. *Vet Anaesth Analg*, 32, 61-71, 2005. DOI: 10.1111/j.1467-2995.2005.00228.x
158. **Gibson TJ, Johnson CB, Stafford KJ, Mitchinson SL, Mellor DJ:** Validation of the acute electroencephalographic responses of calves to noxious stimulus with scoop dehorning. *N Z Vet J*, 55, 152-157, 2007. DOI: 10.1080/00480169.2007.36760
159. **Haga HA, Dolvik NI:** Electroencephalographic and cardiovascular variables as nociceptive indicators in isoflurane-anaesthetized horses. *Vet Anaesth Analg*, 32, 128-135, 2005. DOI: 10.1111/j.1467-2995.2005.00194.x
160. **Haga HA, Ranheim B:** Castration of piglets: The analgesic effects of intratesticular and intrafunicular lidocaine injection. *Vet Anaesth Analg*, 32, 1-9, 2005. DOI: 10.1111/j.1467-2995.2004.00225.x
161. **Hu HZ, Granger N, Pai SB, Bellamkonda RV, Jeffery ND:** Therapeutic efficacy of microtube-embedded chondroitinase ABC in a canine clinical model of spinal cord injury. *Brain*, 141, 1017-1027, 2018. DOI: 10.1093/brain/awy021
162. **Simon MV:** Intraoperative Neurophysiology: A Comprehensive Guide to Monitoring and Mapping. 1-624, Demos Medical, New York, 2009.
163. **Vanderzant CW, Schott RJ, Natale JE, Pondo CA, D'alecy LG:** Somatosensory evoked potentials of the dog: Recording techniques and normal values. *J Neurosci Methods*, 27, 253-263, 1989. DOI: 10.1016/0165-0270(89)90138-4
164. **Poncelet L:** Electrophysiological assessment of spinal cord function through somatosensory evoked potentials in dogs. *Vet Neurol Neurosurg J*, 1:1, 1999.
165. **Schiffman EL (Ed):** A pressure algometer for myofascial pain syndrome: Reliability and validity testing. In, *Proceedings of the 5th World Congress on Pain*. Elsevier, Amsterdam, 1988.
166. **Kaka U, Chen HC, Goh YM, Abubakar AA, Fakurazi S, Ebrahimi M:** Validation of a modified algometer to measure mechanical nociceptive thresholds in awake dogs. *Biomed Res Int*, 2015:375421, 2015. DOI: 10.1155/2015/375421
167. **Coleman KD, Schmiedt CW, Kirkby KA, Coleman AE, Robertson SA, Hash J, Brown J:** Learning confounds algometric assessment of mechanical thresholds in normal dogs. *Vet Surg*, 43, 361-367, 2014. DOI: 10.1111/j.1532-950X.2014.12112.x
168. **Love EJ, Murrell J, Whay HR:** Thermal and mechanical nociceptive threshold testing in horses: A review. *Vet Anaesth Analg*, 38, 3-14, 2011. DOI: 10.1111/j.1467-2995.2010.00580.x
169. **Nussbaum EL, Downes L:** Reliability of clinical pressure-pain algometric measurements obtained on consecutive days. *Phys Ther*, 78, 160-169, 1998. DOI: 10.1093/ptj/78.2.160
170. **Wylde V, Palmer S, Learmonth ID, Dieppe P:** Somatosensory abnormalities in knee OA. *Rheumatology (Oxford)*, 51, 535-543, 2012. DOI: 10.1093/rheumatology/ker343
171. **Slingsby LS, Taylor PM, Murrell JC:** A study to evaluate buprenorphine at 40 µg kg<sup>-1</sup> compared to 20 µg kg<sup>-1</sup> as a post-operative analgesic in the dog. *Vet Anaesth Analg*, 38, 584-593, 2011. DOI: 10.1111/j.1467-2995.2011.00656.x
172. **Hardie EM, Lascelles BDX, Meuten T, Davidson GS, Papich MG, Hansen BD:** Evaluation of intermittent infusion of bupivacaine into surgical wounds of dogs postoperatively. *Vet J*, 190, 287-289, 2011. DOI: 10.1016/j.tvjl.2010.11.008
173. **Fosse TK, Toutain PL, Spadavecchia C, Haga HA, Horsberg TE, Ranheim B:** Ketoprofen in piglets: Enantioselective pharmacokinetics, pharmacodynamics and PK/PD modelling. *J Vet Pharmacol Ther*, 34, 338-349, 2011. DOI: 10.1111/j.1365-2885.2010.01236.x
174. **Moak P, Hosgood G, Rowe E, Lemke KA:** Evaluation of intra-articular and subcutaneous administration of meloxicam for postoperative analgesia following stifle surgery in dogs. *Vet Comp Orthop Traumatol*, 24, 32-38, 2011. DOI: 10.3415/Vcot-10-04-0059
175. **Sammarco JL, Conzemius MG, Perkowski SZ, Weinstein MJ, Gregor TP, Smith GK:** Postoperative analgesia for stifle surgery: A comparison of intra-articular bupivacaine, morphine, or saline. *Vet Surg*, 25, 59-69, 1996. DOI: 10.1111/j.1532-950X.1996.tb01377.x
176. **Grint NJ, Beths T, Yvorchuk K, Whay HR, Murrell JC:** The influence of various confounding factors on mechanical nociceptive thresholds in the donkey. *Vet Anaesth Analg*, 41, 421-429, 2014. DOI: 10.1111/vaa.12149
177. **Desborough JP:** The stress response to trauma and surgery. *Br J Anaesth*, 85, 109-117, 2000. DOI: 10.1093/bja/85.1.109
178. **Lyons FM, Meeran K:** The physiology of the endocrine system. *Int Anesthesiol Clin*, 35, 1-22, 1997. DOI: 10.1097/00004311-199703540-00002
179. **McMahon SB, Cafferty WBJ, Marchand F:** Immune and glial cell factors as pain mediators and modulators. *Exp Neurol*, 192, 444-462, 2005. DOI: 10.1016/j.expneurol.2004.11.001
180. **Wu CT, Jao SW, Borel CO, Yeh CC, Li CY, Lu CH, Wong CS:** The effect of epidural clonidine on perioperative cytokine response, postoperative pain, and bowel function in patients undergoing colorectal surgery. *Anesth Analg*, 99, 502-509, 2004. DOI: 10.1213/01.ANE.0000117146.46373.51
181. **Buvanendran A, Kroin JS, Berger RA, Hallab NJ, Saha C, Negrescu C, Moric M, Tuman KJ:** Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. *Anesthesiology*, 104, 403-410, 2006. DOI: 10.1097/00000542-200603000-00005
182. **Cunha JM, Cunha FQ, Poole S, Ferreira SH:** Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. *Br J Pharmacol*, 130, 1418-1424, 2000. DOI: 10.1038/sj.bjp.0703434
183. **Beilin B, Bessler H, Mayburd E, Smirnov G, Dekel A, Yardeni I, Shavit Y:** Effects of preemptive analgesia on pain and cytokine production in the postoperative period. *Anesthesiology*, 98, 151-155, 2003. DOI: 10.1097/00000542-200301000-00024
184. **Zhang JM, An J:** Cytokines, inflammation, and pain. *Int Anesthesiol Clin*, 45, 27-37, 2007. DOI: 10.1097/AIA.0b013e318034194e

185. **Sheu JY, Kulhanek DJ, Eckenstein FP:** Differential patterns of ERK and STAT3 phosphorylation after sciatic nerve transection in the rat. *Exp Neurol*, 166, 392-402, 2000. DOI: 10.1006/exnr.2000.7508
186. **Herdegen T, Tölle TR, Bravo R, Zieglgänsberger W, Zimmermann M:** Sequential expression of JUN B, JUN D and FOS B proteins in rat spinal neurons: Cascade of transcriptional operations during nociception. *Neurosci Lett*, 129, 221-224, 1991. DOI: 10.1016/0304-3940(91)90466-7
187. **Harris JA:** Using c-fos as a neural marker of pain. *Brain Res Bull*, 45, 1-8, 1998. DOI: 10.1016/S0361-9230(97)00277-3
188. **Karim F, Wang C-C, Gereau RW:** Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. *J Neurosci*, 21, 3771-3779, 2001. DOI: 10.1523/JNEUROSCI.21-11-03771.2001
189. **Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L:** Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem J*, 334, 297-314, 1998. DOI: 10.1042/bj3340297
190. **Ferreira SH, Lorenzetti BB, Bristow AF, Poole S:** Interleukin-1 $\beta$  as a potent hyperalgesic agent antagonized by a tripeptide analogue. *Nature*, 334, 698-700, 1988. DOI: 10.1038/334698a0
191. **Cunha TM, Verri WA, Silva JS, Poole S, Cunha FQ, Ferreira SH:** A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. *Proc Natl Acad Sci USA*, 102, 1755-1760, 2005. DOI: 10.1073/pnas.0409225102
192. **Cunha TM, Verri WA, Valério DA, Guerrero AT, Nogueira LG, Vieira SM, Souza GR, Teixeira MM, Poole S, Ferreira SH, Cunha FQ:** Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice. *Eur J Pain*, 12, 1059-1068, 2008. DOI: 10.1016/j.ejpain.2008.02.003
193. **Watkins LR, Maier SF, Goehler LE:** Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. *Pain*, 63, 289-302, 1995. DOI: 10.1016/0304-3959(95)00186-7
194. **Sommer C, Kress M:** Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. *Neurosci Lett*, 361, 184-187, 2004. DOI: 10.1016/j.neulet.2003.12.007
195. **Üçeyler N, Schäfers M, Sommer C:** Mode of action of cytokines on nociceptive neurons. *Exp Brain Res*, 196, 67-78, 2009. DOI: 10.1007/s00221-009-1755-z
196. **Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF:** Characterization of cytokine-induced hyperalgesia. *Brain Res*, 654, 15-26, 1994. DOI: 10.1016/0006-8993(94)91566-0
197. **Tadano T, Namioka M, Nakagawasai O, Tan-No K, Matsushima K, Endo Y, Kisara K:** Induction of nociceptive responses by intrathecal injection of interleukin-1 in mice. *Life Sci*, 65, 255-261, 1999. DOI: 10.1016/S0024-3205(99)00244-1
198. **Reeve AJ, Patel S, Fox A, Walker K, Urban L:** Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. *Eur J Pain*, 4, 247-257, 2000. DOI: 10.1053/eujp.2000.0177
199. **Falchi M, Ferrara F, Gharib C, Dib B:** Hyperalgesic effect of intrathecally administered interleukin-1 in rats. *Drugs Exp Clin Res*, 27, 97-101, 2001.
200. **Maier SF, Wiertelak EP, Martin D, Watkins LR:** Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. *Brain Res*, 623, 321-324, 1993. DOI: 10.1016/0006-8993(93)91446-Y
201. **Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ:** Contribution of interleukin-1 $\beta$  to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. *Br J Pharmacol*, 115, 1265-1275, 1995. DOI: 10.1111/j.1476-5381.1995.tb15035.x
202. **Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF:** Evidence for the involvement of spinal cord glia in subcutaneous formalin-induced hyperalgesia in the rat. *Pain*, 71, 225-235, 1997. DOI: 10.1016/S0304-3959(97)03369-1
203. **Sweitzer S, Martin D, DeLeo JA:** Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. *Neuroscience*, 103, 529-539, 2001. DOI: 10.1016/S0306-4522(00)00574-1
204. **Beilin B, Shavit Y, Trabekín E, Mordashev B, Mayburd E, Zeidel A, Bessler H:** The effects of postoperative pain management on immune response to surgery. *Anesth Analg*, 97, 822-827, 2003. DOI: 10.1213/01.ANE.0000078586.82810.3B
205. **DeLeo JA, Yezierski RP:** The role of neuroinflammation and neuroimmune activation in persistent pain. *Pain*, 90, 1-6, 2001. DOI: 10.1016/S0304-3959(00)00490-5
206. **Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Woolf CJ:** Interleukin-1 $\beta$ -mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. *Nature*, 410, 471-475, 2001. DOI: 10.1038/35068566
207. **Kroin JS, Ling ZD, Buvanendran A, Tuman KJ:** Upregulation of spinal cyclooxygenase-2 in rats after surgical incision. *Anesthesiology*, 100, 364-369, 2004. DOI: 10.1097/00000542-200402000-00027
208. **Wordliczek J, Szczepanik AM, Banach M, Turchan J, Zembala M, Siedlar M, Przewłocka B:** The effect of pentoxifylline on post-injury hyperalgesia in rats and postoperative pain in patients. *Life Sci*, 66, 1155-1164, 2000. DOI: 10.1016/S0024-3205(00)00419-7
209. **Lu CH, Chao PC, Borel CO, Yang CP, Yeh CC, Wong CS, Wu CT:** Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel function in patients undergoing colorectal cancer surgery. *Anesth Analg*, 99, 1465-1471, 2004. DOI: 10.1213/01.ANE.0000132974.32249.C8
210. **Hung AL, Lim M, Doshi TL:** Targeting cytokines for treatment of neuropathic pain. *Scand J Pain*, 17 (1): 287-293, 2017. DOI: 10.1016/j.sjpain.2017.08.006
211. **Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, Jena AB:** The interplay between cytokines, inflammation, and antioxidants: Mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. *Biomed Pharmacother*, 178:117177, 2024. DOI: 10.1016/j.biopha.2024.117177
212. **Mills EP, Keay KA, Henderson LA:** Brainstem pain-modulation circuitry and its plasticity in neuropathic pain: Insights from human brain imaging investigations. *Front Pain Res*, 2:705345, 2021. DOI: 10.3389/fpain.2021.705345
213. **Lahimchi MR, Eslami M, Yousefi B:** Interleukin-35 and interleukin-37 anti-inflammatory effect on inflammatory bowel disease: Application of non-coding RNAs in IBD therapy. *Int Immunopharmacol*, 117:109932, 2023. DOI: 10.1016/j.intimp.2023.109932
214. **Su Z, Tao X:** Current understanding of IL-37 in human health and disease. *Front Immunol*, 12:696605, 2021. DOI: 10.3389/fimmu.2021.696605
215. **Han ZA, Song DH, Oh HM, Chung ME:** Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. *Ann Neurol*, 79, 569-578, 2016. DOI: 10.1002/ana.24609
216. **Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, Raicher I, Üçeyler N, Sommer C, Bouhassira D:** Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. *Lancet Neurol*, 15, 555-565, 2016. DOI: 10.1016/S1474-4422(16)00017-X
217. **Duffy SS, Keating BA, Perera CJ, Lees JG, Tonkin RS, Makker PG, Barton SK, Wright A, Moalem-Taylor G:** Regulatory T cells and their derived cytokine, interleukin-35, reduce pain in experimental autoimmune encephalomyelitis. *J Neurosci*, 39, 2326-2346, 2019. DOI: 10.1523/JNEUROSCI.1815-18.2019
218. **Jiang S, Xu L, Xu Y, Guo Y, Wei L, Li X, Song W:** Antidiabetic effect of *Momordica charantia* saponins in rats induced by high-fat diet

- 
- combined with STZ. *Electron J Biotechnol*, 43, 41-47, 2020. DOI: 10.1016/j.ejbt.2019.12.001
219. **Zeng H, Zhou K, Ye Z:** Biology of interleukin37 and its role in autoimmune diseases. *Exp Ther Med*, 24 (2):462, 2022. DOI: 10.3892/etm.2022.11449
220. **Zanjani TM, Sabetkasaei M, Karimian B, Labibi F, Farokhi B, Mossafa N:** The attenuation of pain behaviour and serum interleukin-6 concentration by nimesulide in a rat model of neuropathic pain. *Scand J Pain*, 1, 229-234, 2010. DOI: 10.1016/j.sjpain.2010.08.003
221. **Zulkifli I, Goh YM, Norbaiyah B, Sazili AQ, Lotfi M, Soleimani AE, Rajion MA:** Changes in blood parameters and electroencephalogram of cattle as affected by different stunning and slaughter methods in cattle. *Anim Prod Sci*, 54, 187-193, 2014. DOI: 10.1071/AN12128
222. **Livingston A, Waterman AE, Chambers JP (Eds):** Neurologic evaluation of effective post-operative pain therapy. In, *Proceedings 226: Animal Pain and Its Control*. Post Graduate Committee in Veterinary Science, Sydney, 1994.